Original Article
A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia
N Engl J Med 1994; 331:1325-1330November 17, 1994
- Abstract
Background
Amphotericin B has long been the standard treatment for candidemia, but its use is complicated by its toxicity. More recently, fluconazole, a water-soluble triazole with activity against candida species and little toxicity, has become available. We conducted a multicenter randomized trial that compared amphotericin B with fluconazole as treatment for candidemia.
Methods
To be eligible, patients had to have a positive blood culture for candida species, a neutrophil count ≥ 500 per cubic millimeter, and no major immunodeficiency. Patients were randomly assigned to receive either amphotericin B (0.5 to 0.6 mg per kilogram of body weight per day) or fluconazole (400 mg per day), each continued for at least 14 days after the last positive blood culture. Outcomes were assessed by a group of investigators blinded to treatment assignment.
Results
Of the 237 patients enrolled, 206 met all entry criteria. The most common diagnoses were renal failure, nonhematologic cancer, and gastrointestinal disease. There was no statistically significant difference in outcome: of the 103 patients treated with amphotericin B, 81 (79 percent) were judged to have been treated successfully, as were 72 of the 103 patients treated with fluconazole (70 percent; P = 0.22; 95 percent confidence interval for the difference, -5 to 23 percent). The bloodstream infection failed to clear in 12 patients in the amphotericin group and 15 in the fluconazole group; the species most commonly associated with failure was Candida albicans. There were 41 deaths in the amphotericin group and 34 deaths in the fluconazole group (P = 0.20). Intravascular catheters appeared to be the most frequent source of candidemia. There was less toxicity with fluconazole than with amphotericin B.
Conclusions
In patients without neutropenia and without major immunodeficiency, fluconazole and amphotericin B are not significantly different in their effectiveness in treating candidemia.
Media in This Article
Table 1
Enrollment of the Study Patients.Table 2
Base-Line Characteristics of the Study Patients.Article Activity
- Article
There has been substantial controversy over the treatment of patients with candidemia. Descriptions of transient candidemia caused by venous catheters1 led initially to the conclusion that some episodes might not require treatment. Recent data have, however, documented mortality rates of 46 to 75 percent for a wide variety of patients with candidemia,2-7 and the excess mortality attributable to candidemia has been estimated at 38 percent8. These data have led to recommendations that all patients with candidemia receive some form of antifungal therapy9. Amphotericin B has long been the mainstay of treatment, but its toxicity -- which complicates the treatment of critically ill patients and seems excessive in less severely ill patients -- led many to question its role in some groups of patients. One possible alternative is fluconazole, an antifungal agent that has both oral and parenteral formulations, has minimal toxic effects, and is effective in the treatment of mucosal candidiasis, including esophagitis10,11. These properties make it attractive for treating candidemia. We conducted a randomized, multicenter comparative trial of fluconazole and amphotericin B for the treatment of candidemia among patients without neutropenia.
Methods
Patients
To be enrolled in the trial, patients had to be at least 13 years old and to have had at least one positive blood culture for candida species during the previous four days. In addition, at some time between the first positive blood culture and enrollment the patient had to have had a temperature of at least 38.6 °C on one occasion or a temperature of at least 37.8 °C on two occasions at least four hours apart, a systolic blood pressure of less than 100 mm Hg or a decrease in systolic blood pressure of at least 30 mm Hg from base line, or some sign of inflammation (swelling, heat, erythema, or purulence) at a site infected with candida. Patients were excluded if they had neutrophil counts of less than 500 per cubic millimeter, had a hematologic cancer, had a congenital immunodeficiency syndrome, were known to be seropositive for human immunodeficiency virus type 1, had received organ transplants, had burns on more than 30 percent of the body, had histories of allergy or intolerance to imidazoles or azoles, or had moderate-to-severe liver disease (defined as a level of alkaline phosphatase, aspartate aminotransferase, or alanine aminotransferase greater than five times the upper limit of normal, a total serum bilirubin level higher than 8 mg per deciliter [137 μmol per liter], or a prothrombin time exceeding the upper limit of normal by at least five seconds and not correctable with vitamin K). Patients were also excluded if they were deemed unlikely to survive for at least 24 hours, had received more than 0.6 mg of amphotericin B per kilogram of body weight or 400 mg of fluconazole within the previous 14 days, had already undergone unsuccessful systemic antifungal therapy for the same infection, had previously participated in this trial, or were receiving investigational drugs, approved drugs for investigational indications, immunostimulants, lymphocyte-replacement therapy, or cancer chemotherapy that was likely to cause neutropenia during the study period. Women of childbearing age could not be pregnant or lactating, were required to have negative results on a pregnancy test, and were required to use adequate contraception during the course of the trial. Informed consent was obtained from all patients or their families, and the study was reviewed and approved by the institutional review board of each center.
Study Protocol
After enrollment, the patients were randomly assigned in equal numbers to receive fluconazole or amphotericin B on the basis of a sequential list of block-randomized assignments maintained by the pharmacy at each participating institution. The treatment assignments were not known to investigators or patients before enrollment and randomization, but because of the disparate properties of the two drugs it was not possible to maintain blinding after randomization. Patients were to continue to be given the assigned study drug for at least 14 days after the resolution of clinical findings related to the episode of candidemia or at least 14 days after the last positive deep-site (normally sterile) culture was obtained, whichever was longer. Patients assigned to receive fluconazole were given 400 mg per day in a single dose. Fluconazole was administered intravenously for the first seven days of therapy and then by mouth unless the patient's condition precluded reliable oral therapy. If the patient weighed more than 90 kg or less than 50 kg, the dose of fluconazole was the multiple of 50 that was closest to, but did not exceed, 6 mg per kilogram. The dose of fluconazole was decreased by 50 percent in patients whose estimated creatinine clearance was less than 50 ml per minute and by 75 percent in patients whose estimated clearance was less than 20 ml per minute. Patients assigned to receive amphotericin B were given 0.5 to 0.6 mg per kilogram per day intravenously for the first seven days of therapy. After seven days, the drug could be administered approximately three times per week, as long as the average daily dose was 0.5 to 0.6 mg per kilogram. We recommended that therapy begin with a 1-mg test dose, followed by prompt escalation to the full daily dose over no more than three days. Concomitant use of any combination of acetaminophen, ibuprofen, diphenhydramine, hydrocortisone (up to 50 mg per day), and meperidine was allowed.
Patients were evaluated at the time of entry into the study, daily during therapy, and 2, 6, and 12 weeks after therapy was completed. Two blood cultures were obtained at base line, on days 2, 4, and 7 of therapy, twice weekly during the remainder of the therapy, and again at the two- and six-week follow-up examinations. After enrollment, blood cultures were performed according to the Isolator system (Wampole Laboratories, Cranbury, N.J.). Hemoglobin, hematocrit, leukocyte count, platelet count, prothrombin time, serum creatinine, electrolytes, alkaline phosphatase, total bilirubin, alanine aminotransferase, and aspartate aminotransferase were measured twice weekly during the course of therapy. Either drug could be discontinued if the patient's infection was unresponsive or progressive after five or more days of therapy. Fluconazole was to be stopped if there were marked adverse effects on the liver (defined as a level of alkaline phosphatase 1.5 times the greater of the upper limit of normal or the base-line value, a level of aspartate or alanine aminotransferase 3 times the greater of the upper limit of normal or the base-line value, or a total serum bilirubin level 3 times the greater of the upper limit of normal or the base-line value). If the serum creatinine level rose above 3.5 mg per deciliter (309 μmol per liter) in a patient treated with amphotericin, the investigator was to alter the timing and amount of amphotericin B therapy. Modification of the dosage could include either temporary or permanent cessation of amphotericin B therapy. In the event either drug was discontinued, treatment was scored as a failure only if additional systemic antifungal therapy was subsequently administered.
After the conclusion of therapy and follow-up, case-report forms were purged of information that might identify the study drugs by two of the investigators and then scored in a blinded fashion by four other investigators. Treatment was considered successful if all signs and symptoms of the candida infection resolved, blood cultures obtained at the end of therapy and at the follow-up visits were negative, and cultures from normally sterile sites previously positive for candida became negative and any associated signs of local inflammation resolved. Treatment was considered to have failed if there was unresponsive or progressive infection after five or more days of therapy or if unacceptable side effects necessitated a change in antifungal therapy. Treatment was also considered to have failed if a patient withdrew from the study before improvement or failure had been clearly documented. Cases considered to be successes at the end of study therapy were reclassified as relapses if there was a positive blood culture for candida, a visceral candida infection was discovered, or more than four days of antifungal therapy was given for an asymptomatic candida urinary tract infection or any amount of antifungal therapy was given for any other cause. Finally, the local investigators identified three cases in which there was strong evidence that the patients had induced their episodes of candidemia by manipulating intravenous catheters. The blinded reviewers scored these patients on the basis of their responses to the initial course of therapy and ignored later events. The blinded reviewers also excluded data on these patients from the analysis of therapy lasting five or more days but retained them in the primary and intention-to-treat analyses.
Statistical Analysis
The primary analysis in this trial was specified in advance as a comparison of the response rates (successes vs. failures and relapses) for the patients meeting all entry criteria. The null hypothesis was that the difference between the proportions of patients with favorable responses in the two groups would be less than 20 percent. To test this hypothesis with a power of 80 percent and a significance level of 5 percent, 90 patients were needed in each group for the primary analysis. Unless otherwise specified, all analyses pertain to this sample. Two secondary analyses were specified in advance: an intention-to-treat analysis of all patients who enrolled in the trial and had candidemia, whether or not they met all entry criteria, and an analysis of the outcome in patients who received at least five days of therapy. Outcome analyses were performed as two-sided Cochran-Mantel-Haenszel tests. Other post hoc tests were performed as indicated. Data are reported as means ±SE and sometimes include the 80 percent range that spans the 10th to 90th percentiles.
Results
Enrollment and Base-Line Characteristics of the Patients
Between December 1989 and April 1993, 237 patients were enrolled at 24 centers (Table 1Table 1
Enrollment of the Study Patients.). The patients in the two study groups in the primary analysis had similar characteristics at base line (Table 2Table 2Base-Line Characteristics of the Study Patients.). Acute Physiology and Chronic Health Evaluation (APACHE II) scores12 were computed at study entry.Microbiology
Candida albicans was the most common infecting species, and 59 percent of the patients were infected with this species alone (Table 3Table 3
Distribution of Infecting Species.). The first positive blood culture was obtained 2.6 ±0.1 days before study entry for patients in both treatment groups.Peripheral venipuncture was the source of one or more positive blood cultures in 131 of the 206 patients (64 percent). In another 32 patients (16 percent) all positive blood cultures were known to have been drawn through catheters. In the remaining 43 patients (21 percent), the sites of the positive blood cultures were not clearly documented.
Vascular catheters were judged to be the most probable source of candidemia in 149 patients (72 percent) (Table 4Table 4
Apparent Sources of Candidemia.).Course of Therapy
Patients in the amphotericin B group were treated for 17 ±1 days (80 percent range, 6 to 30) and received 0.5 ±0.01 mg of drug per kilogram per day (80 percent range, 0.3 to 0.6), for a total dose of 570 ±40 mg (80 percent range, 140 to 1080). Patients in the fluconazole group were treated for 18 ±1 days (80 percent range, 6 to 34), and received an average of 5.3 ±0.2 mg of drug per kilogram per day (80 percent range, 2.7 to 7.8) during this time. The number of days of therapy did not differ significantly in the two study groups (P = 0.56 by Student's t-test).
Toxicity
Elevations in blood urea nitrogen or serum creatinine levels were judged by the blinded review committee to have occurred in 37 percent of the patients treated with amphotericin B and 2 percent of those treated with fluconazole (P<0.001 by Fisher's exact test). Hypokalemia developed in 10 percent of the patients in the amphotericin B group and 2 percent of those in the fluconazole group (P = 0.006). Liver enzymes became elevated in 10 percent of the amphotericin B group and 14 percent of the fluconazole group (P = 0.43).
Outcome
There was no statistically significant difference in outcome between the two study groups in the primary analysis: 81 of the patients treated with amphotericin B (79 percent) had successful outcomes, as did 72 of the patients treated with fluconazole (70 percent) (P = 0.22; 95 percent confidence interval for the difference, -5 to 23 percent). Similarly, in the intention-to-treat analysis 89 of 111 patients treated with amphotericin B (80 percent) and 81 of 113 patients treated with fluconazole (72 percent) had successful outcomes (P = 0.17; 95 percent confidence interval for the difference, -3 to 20 percent). Finally, in the secondary analysis of patients treated for at least five days, 81 of 94 patients given amphotericin B (86 percent) and 70 of 93 patients given fluconazole (75 percent) had successful outcomes (P = 0.05; 95 percent confidence interval for the difference, 0 to 18 percent).
Analysis of Failures and Relapses
The bloodstream infection failed to clear in 12 patients treated with amphotericin B and 15 treated with fluconazole. The organism most commonly associated with failure in both groups was C. albicans (Table 5Table 5
Causes of Treatment Failure and Relapse.). The patients treated with amphotericin B received 0.5 ±0.04 mg of drug per kilogram per day (80 percent range, 0.25 to 0.65), for a total of 4.5 ±0.9 mg per kilogram (80 percent range, 0.5 to 9.6) given over a period of 8.7 ±1.5 days (80 percent range, 2 to 17) before the patient died or treatment failure was declared. Eight of these patients died, seven as a direct result of the episode of candidemia (see below). The 15 patients treated with fluconazole received 5.5 ±0.5 mg per kilogram per day (80 percent range, 3.1 to 8.4) for 8.3 ±1.4 days (80 percent range, 4 to 17). Nine of these patients died, five as a direct result of the episode of candidemia. The mean duration of therapy before the declaration of failure did not differ between treatment groups (P = 0.9). There was also no statistically significant difference in the rate of failure to clear any species, although the power to detect a difference was limited for species other than C. albicans.Increases in serum creatinine levels led to the discontinuation of the study drug in three patients receiving amphotericin B, and increases in alanine and aspartate aminotransferase levels led to the discontinuation of the study drug in two patients receiving fluconazole.
The bloodstream infection cleared in four patients receiving fluconazole, but their therapy was altered because fever either persisted or recurred late in the course of treatment. In three of these patients, no site was positive for candida species; C. albicans was found in a sputum culture from the fourth. In one patient treated with fluconazole a blood culture drawn on day 4 yielded Saccharomyces cerevisiae on day 11. Since the patient was also still febrile, therapy was changed to amphotericin B. The fever persisted for an additional two weeks. Two patients treated with fluconazole had persistent peritoneal candida infections. Finally, four patients given amphotericin B and three given fluconazole withdrew from the study after four days or less of therapy. The reviewers judged them impossible to evaluate, and they were scored as having had treatment failures.
In one patient given amphotericin B, a perinephric abscess due to candida developed after a 47-day course of therapy, and one patient given fluconazole presented with a candida abscess at the site of a recent glioma resection after a 16-day course of therapy. Two patients in the amphotericin B group had unexplained hypotension early in the follow-up period, and systemic antifungal therapy was reinstituted. Neither patient had positive cultures for candida during the episode. Finally, one patient in the amphotericin B group and three in the fluconazole group had candiduria during follow-up without fever or leukocytosis and were treated with more than four days of systemic antifungal agents. Although the initial courses of therapy were successful in these patients, the use of systemic antifungal agents during follow-up required that their treatments be scored as failures. In a post hoc analysis, these four technical failures were rescored as successes. Under these scoring rules, there was no difference in outcome in the primary analysis: 82 patients treated with amphotericin B (80 percent) had successful outcomes, as did 75 patients treated with fluconazole (73 percent) (P = 0.40; 95 percent confidence interval for the difference, -9 to 23 percent). Similarly, there were no statistically significant differences in the intention-to-treat analysis (success rates of 81 percent and 74 percent, respectively; P = 0.31; 95 percent confidence interval for the difference, -6 to 20 percent) or the five-or-more-days-of-therapy analysis (success rates of 87 percent and 78 percent; P = 0.14; 95 percent confidence interval for the difference, -3 to 21 percent).
Follow-up and Deaths
The patients given amphotericin B were followed for 61 ±5 days after the end of therapy, and those given fluconazole were followed for 65 ±5 days (P = 0.6). During this time, 41 of 103 patients in the amphotericin B group (40 percent) and 34 of 103 in the fluconazole group (33 percent) died (P = 0.20), with no statistically significant difference in the length of time until death (P = 0.20) or in the number of deaths in the first seven days of therapy (10 in the amphotericin B group and 5 in the fluconazole group, P = 0.28). If a patient had a positive blood culture within 48 hours of death or had evidence of visceral candidiasis at autopsy, the episode of candidemia was judged to be directly contributory to death. There were eight such deaths in the amphotericin B group and seven in the fluconazole group. The results of the intention-to-treat and five-or-more-days-of-therapy analyses were also not statistically significant (data not shown).
The predetermined scoring rules made it possible for treatment to be scored as a success although the patient died on or shortly after the last day of therapy. A post hoc analysis was performed in which all the patients who died within 14 days after therapy ended were scored as having had treatment failures. Under these rules, 68 of 103 patients treated with amphotericin B (66 percent) had successful outcomes, as did 64 of 103 patients treated with fluconazole (62 percent) (P = 0.66; 95 percent confidence interval for the difference, -14 to 22 percent). Results were similar for the intention-to-treat analysis, the five-or-more-days-of-therapy analysis, and an analysis in which death within seven days after the end of therapy was considered to indicate treatment failure (data not shown).
Management of Intravascular Catheters
Complete catheter records were available for 91 percent of both study groups. Sixty-two patients in each group underwent complete catheter exchanges (a complete catheter exchange was defined as the removal and replacement of all catheters on a single day) on or before the first day of treatment with the study drug. The exchange was performed over a guidewire placed through a preexisting catheter in 10 patients in the amphotericin B group and 7 in the fluconazole group.
Endophthalmitis
Ninety-four percent of the patients underwent ocular examinations before the end of therapy. Thirteen in the amphotericin B group and 16 in the fluconazole group had retinal findings consistent with candida endophthalmitis13. In one patient in the fluconazole group with persistent fungemia, a lesion persisted and enlarged despite subsequent amphotericin B therapy. Vitrectomy was ultimately required for cure. In no other patient did a lesion cause problems, and no patient had candida endophthalmitis after the end of therapy; of the 127 patients who reached the 2-week or 6-week follow-up point, 108 (85 percent) had either normal ophthalmologic results or no ocular symptoms at 12 weeks. No such follow-up information was available for the remaining 19 patients.
Discussion
We studied a large series of patients with candidemia. Beyond a slight disparity in sex, the two study groups were comparable with respect to age and risk factors for candidemia. It is noteworthy that the mean APACHE II scores were identical (16 ±1).
There were no statistically significant differences between amphotericin B and fluconazole as treatments for candidemia in the primary and intention-to-treat analyses. Amphotericin B had a marginally significant higher success rate than fluconazole in a secondary analysis of patients treated for at least five days, but this analysis is potentially biased because of early withdrawal from this unblinded trial. Analyzed in detail (Table 5), the differences between the two groups were not due to persistent candidemia (12 percent in the amphotericin B group and 15 percent in the fluconazole group), toxicity (3 percent and 2 percent), or deaths (40 percent and 33 percent), but to therapeutic modifications late in the course of therapy or after the end of therapy. Particularly troubling were patients who received systemic antifungal therapy for asymptomatic funguria during follow-up. These patients represented treatment failures according to our predefined scoring system, but this determination obscures the patients' initial responses to therapy and otherwise benign follow-up courses. Another aspect of our scoring system was that it did not require survival beyond the end of therapy. When, in a post hoc analysis, success was redefined to require survival for 7 or 14 days after therapy ended, the success rates for the two drugs became essentially identical. The most frequent site of secondary spread appears to have been the eye, with retinal lesions in 29 patients. Other than one late abscess in each study group, no other hematogenous sequelae of candidemia were noted.
Seventy-five of the 206 patients in our primary analysis died, for an overall mortality rate of 36 percent. Although the lack of comparable demographic data in other published studies of patients with candidemia makes comparisons difficult, this rate is below the 46 to 75 percent reported for patients with primarily nononcologic illnesses2-5 and the 63 to 72 percent reported for studies that included primarily patients with cancer2,6,7.
This study had several limitations. First, the properties of the study drugs made blinding impossible. Although records were reviewed in a blinded fashion by an oversight committee, local study investigators were not blinded as regards treatment drugs, and decisions to change antifungal regimens would cause the patients' treatments to be scored as failures under all circumstances. Second, we were unable to control the management of intravascular catheters as part of the trial. Fortunately, however, analysis of catheter management demonstrated that a similar proportion of catheters was exchanged in each study group. Finally, it should be emphasized that our data apply only to patients without neutropenia and with relatively little immunosuppression.
In conclusion, fluconazole and amphotericin B do not differ significantly as therapy for candidemia in patients without neutropenia who are not severely immunocompromised. The most common source of candidemia in our study appeared to be intravascular catheters, and the investigators at all our centers attempted to change all intravascular catheters that were in place at the time of candidemia. Our study was not large enough to determine whether patients infected with species other than C. albicans were less likely to respond to either drug, but no striking discrepancies were apparent. Too few late complications were seen to permit meaningful comparison. We do not know whether timely catheter exchanges or systemic antifungal therapy accounts for the low incidence of late complications, but we believe both to be essential components of management.
Presented in part at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, October 18-20, 1993 (abstract no. 805) and at the 12th Congress of the International Society for Human and Animal Mycology, Adelaide, Australia, March 13-18, 1994 (abstract no. S11.1).
Supported by grants from Roerig-Pfizer and in part by a contract (N01-AI-15082) to the Mycoses Study Group from the National Institute of Allergy and Infectious Diseases.
Source Information
From the University of Texas Medical School at Houston, Houston (J.H.R.); Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, Bethesda, Md. (J.E.B.); Boston University Medical Center Hospital, Boston (A.M.S.); University of Alabama, Birmingham (P.G.P.); University of North Carolina, Chapel Hill (C.M.V.); Harbor-UCLA Medical Center, Torrance, Calif. (J.E.E.); Bowman Gray School of Medicine, Winston-Salem, N.C. (R.G.W.); University of Virginia, Charlottesville (W.M.S.); New England Deaconess Hospital, Boston (A.W.K.); and Roerig-Pfizer, New York (A.P.D., M.J.L., C.D.W.).
Address reprint requests to Dr. Rex at the University of Texas Medical School, 6431 Fannin 1728 JFB, Houston, TX 77030.
Additional contributing authors include Harold C. Neu, M.D., John J. Stern, M.D., Carmelita U. Tuazon, M.D., Robert H. Rubin, M.D., Bryan P. Simmons, M.D., Jack D. Sobel, M.D., Michael F. Parry, M.D., James M. Horton, M.D., Issa E. Ephthimios, M.D., Allan R. Tunkel, M.D., Ph.D., Ronald A. Greenfield, M.D., Winkler G. Weinberg, M.D., David S. McKinsey, M.D., and Corstiaan Brass, M.D.
Appendix
The following investigators also participated in this study: Boston University Medical Center Hospital, Boston: C. Saunders; University of Alabama, Birmingham: L. Riser and M.E. Bradley; University of North Carolina, Chapel Hill: J. Serody and B. Longmire; Harbor-UCLA Medical Center, Torrance, Calif.: S. Filler; Bowman Gray School of Medicine, Winston-Salem, N.C.: J. Sinclair; University of Virginia, Charlottesville: C. Sable and J. White; New England Deaconess Hospital, Boston: M. Golden and E. Levin; Columbia University, New York: P. Doerney; Pennsylvania Hospital, Philadelphia: M. Buckley, M.N. Braffman, and N. Pietroski; George Washington University Medical Center, Washington, D.C.: S. McMullen; Massachusetts General Hospital, Boston: A. Delvecchio; Methodist Hospital of Memphis, Memphis, Tenn.: M. Gelfand and B. Craft; Wayne State University, Detroit: L. Flatt; Stamford Hospital, Stamford, Conn.: D. Adler-Klein; Carolinas Medical Center, Charlotte, N.C.: J. Connell; University of Iowa College of Medicine, Iowa City: B.N. Doebbeling, R.P. Wenzel, and C. Leick; Medical College of Pennsylvania, Philadelphia: C.C. Johnson and P. Walsh; University of Oklahoma Health Sciences Center, Oklahoma City: D. Filippo; Infectious Diseases Research Consortium of Georgia, Atlanta: D. Blum; Research Medical Center, Kansas City, Mo.: B. Lee; Buffalo Medical Group, Buffalo, N.Y.: J. Fenner; Middleton Memorial Veterans Affairs Medical Center, Madison, Wis.: J.M. Jones; National Institute of Allergy and Infectious Diseases Mycoses Study Group, University of Alabama, Birmingham: W.E. Dismukes, J.Y. Lee, and G.A. Cloud; and Roerig-Pfizer, New York: S. Elkin, P. Eisman, A. Feldman, J. Foulkes, S. Morrison, and C. Petrucelli.
- References
References
1
Ellis CA ,Spivack ML . The significance of candidemia. Ann Intern Med 1967;67:511-522
Web of Science | Medline2
Fraser VJ ,Jones M ,Dunkel J ,Storfer S ,Medoff G ,Dunagan WC . Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992;15:414-421
CrossRef | Web of Science | Medline3
Marsh PK ,Tally FP ,Kellum J ,Callow A ,Gorbach SL . Candida infections in surgical patients. Ann Surg 1983;198:42-47
CrossRef | Web of Science | Medline4
Klein JJ ,Watanakunakorn C . Hospital-acquired fungemia: its natural course and clinical significance. Am J Med 1979;67:51-58
CrossRef | Web of Science | Medline5
Harvey RL ,Myers JP . Nosocomial fungemia in a large community teaching hospital. Arch Intern Med 1987;147:2117-2120
CrossRef | Web of Science | Medline6
Komshian SV ,Uwaydah AK ,Sobel JD ,Crane LR . Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989;11:379-390
CrossRef | Medline7
Horn R ,Wong B ,Kiehn TE ,Armstrong D . Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis 1985;7:646-655
CrossRef | Medline8
Wey SB ,Mori M ,Pfaller MA ,Woolson RF ,Wenzel RP . Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642-2645
CrossRef | Web of Science | Medline9
Edwards JE Jr . Should all patients with candidemia be treated with antifungal agents? Clin Infect Dis 1992;15:422-423
CrossRef | Web of Science | Medline10
Richardson K ,Cooper K ,Marriott MS ,Tarbit MH ,Troke PF ,Whittle PJ . Discovery of fluconazole, a novel antifungal agent. Rev Infect Dis 1990;12:Suppl 3:S267-S271
CrossRef | Medline11
Laine L ,Dretler RH ,Conteas CN , et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS: a randomized trial. Ann Intern Med 1992;117:655-660
Web of Science | Medline12
Knaus WA ,Draper EA ,Wagner DP ,Zimmerman JE . APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-829
CrossRef | Web of Science | Medline13
Edwards JE Jr ,Foos RY ,Montgomerie JZ ,Guze LB . Ocular manifestations of Candida septicemia: review of seventy-six cases of hematogenous Candida endophthalmitis. Medicine (Baltimore) 1974;53:47-75
CrossRef | Web of Science | Medline
- Citing Articles (365)
Citing Articles
1
Jay Chhablani. (2011) Fungal endophthalmitis. Expert Review of Anti-infective Therapy 9:12, 1191-1201
CrossRef2
Jesús Fortún. (2011) Actualización en terapia antifúngica: nuevos fármacos e indicaciones. Enfermedades Infecciosas y Microbiología Clínica 29, 38-44
CrossRef3
Mahipal Sinnollareddy, Sandra L Peake, Michael S Roberts, E Geoffrey Playford, Jeffrey Lipman, Jason A Roberts. (2011) Pharmacokinetic evaluation of fluconazole in critically ill patients. Expert Opinion on Drug Metabolism & Toxicology 7:11, 1431-1440
CrossRef4
Cornelia Lass-Flörl. (2011) Triazole Antifungal Agents in Invasive Fungal Infections. Drugs1
CrossRef5
Nicolas Allou, Jerome Allyn, Philippe Montravers. (2011) When and How to Cover for Fungal Infections in Patients with Severe Sepsis and Septic Shock. Current Infectious Disease Reports 13:5, 426-432
CrossRef6
M. Karthaus, M. J. G. T. Rüping, O. A. Cornely, A. Steinbach, A. H. Groll, C. Lass-Flörl, H. Ostermann, M. Ruhnke, J. J. Vehreschild. (2011) Current issues in the clinical management of invasive candida infections - the AGIHO, DMykG, ÖGMM and PEG web-based survey and expert consensus conference 2009. Mycoses 54:5, e546-e556
CrossRef7
A. Glöckner, M. Karthaus. (2011) Current aspects of invasive candidiasis and aspergillosis in adult intensive care patients. Mycoses 54:5, 420-433
CrossRef8
John R Perfect. (2011) Azoles: back to the future. Current Opinion in Infectious Diseases 24, S41-S58
CrossRef9
R. E. Lewis. (2011) Current Concepts in Antifungal Pharmacology. Mayo Clinic Proceedings 86:8, 805-817
CrossRef10
Markus Ruhnke, Volker Rickerts, Oliver A. Cornely, Dieter Buchheidt, Andreas Glöckner, Werner Heinz, Rainer Höhl, Regine Horré, Meinolf Karthaus, Peter Kujath, Birgit Willinger, Elisabeth Presterl, Peter Rath, Jörg Ritter, Axel Glasmacher, Cornelia Lass-Flörl, Andreas H. Groll. (2011) Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses 54:4, 279-310
CrossRef11
Po-Lin Chen, Hsiu-Jung Lo, Chi-Jung Wu, Hsin-Chun Lee, Chia-Ming Chang, Nan-Yao Lee, An-Huei Wang, Wen-Liang Lin, Nai-Ying Ko, Ching-Chi Lee, Wen-Chien Ko. (2011) Species distribution and antifungal susceptibility of blood Candida isolates at a tertiary hospital in southern Taiwan, 1999-2006. Mycoses 54:4, e17-e23
CrossRef12
P. Montravers, J.-P. Mira, J.-P. Gangneux, O. Leroy, O. Lortholary, . (2011) A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clinical Microbiology and Infection 17:7, 1061-1067
CrossRef13
Lauren Piper, P. Brian Smith, Christoph P. Hornik, Ira M. Cheifetz, Jeffrey S. Barrett, Ganesh Moorthy, William W. Hope, Kelly C. Wade, Michael Cohen-Wolkowiez, Daniel K. Benjamin. (2011) Fluconazole Loading Dose Pharmacokinetics and Safety in Infants. The Pediatric Infectious Disease Journal 30:5, 375-378
CrossRef14
Benito Almirante, Manuel Cuenca-Estrella. (2011) Candidemia: impacto de los estudios epidemiológicos en la terapéutica y en el pronóstico de una infección grave. Enfermedades Infecciosas y Microbiología Clínica 29:5, 325-327
CrossRef15
José María Aguado, Isabel Ruiz-Camps, Patricia Muñoz, José Mensa, Benito Almirante, Lourdes Vázquez, Montserrat Rovira, Pilar Martín-Dávila, Asunción Moreno, Francisco Álvarez-Lerma, Cristóbal León, Luis Madero, Jesús Ruiz-Contreras, Jesús Fortún, Manuel Cuenca-Estrella. (2011) Recomendaciones sobre el tratamiento de la candidiasis invasiva y otras infecciones por levaduras de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2011. Enfermedades Infecciosas y Microbiología Clínica 29:5, 345-361
CrossRef16
Melanie W. Pound, Mary L. Townsend, Vincent Dimondi, Dustin Wilson, Richard H. Drew. (2011) Overview of treatment options for invasive fungal infections. Medical Mycology1-20
CrossRef17
Jutta Auberger, Cornelia Lass-Flörl. (2011) Current evidence for the treatment of invasive fungal infections in immunocompromised patients. Clinical Investigation 1:3, 447-457
CrossRef18
Marcio Nucci. (2011) Persistent Candidemia: Causes and Investigations. Current Fungal Infection Reports 5:1, 3-11
CrossRef19
Necdet Kuyucu. (2011) Amphotericin B use in children: conventional and lipid-based formulations. Expert Review of Anti-infective Therapy 9:3, 357-367
CrossRef20
Kevin Watt, Daniel K. Benjamin, Michael Cohen-Wolkowiez. (2011) Pharmacokinetics of antifungal agents in children. Early Human Development 87, S61-S65
CrossRef21
Jennifer F. Ha, Claire M. Italiano, Christopher H. Heath, Sophia Shih, Suzanne Rea, Fiona M. Wood. (2011) Candidemia and invasive candidiasis: A review of the literature for the burns surgeon. Burns 37:2, 181-195
CrossRef22
Ana Filipa Bastos Pedrosa, Acácio Gonçalves Rodrigues. (2011) Candidemia in Burn Patients: Figures and Facts. The Journal of Trauma: Injury, Infection, and Critical Care 70:2, 498-506
CrossRef23
Anna K. Person, Dimitrios P. Kontoyiannis, Barbara D. Alexander. (2011) Fungal Infections in Transplant and Oncology Patients. Hematology/Oncology Clinics of North America 25:1, 193-213
CrossRef24
Alexander Lepak, David Andes. (2011) Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting. Critical Care Clinics 27:1, 123-147
CrossRef25
A Glöckner. (2011) Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin - review of the literature. European Journal of Medical Research 16:4, 167
CrossRef26
M.A. Pfaller, D. Andes, D.J. Diekema, A. Espinel-Ingroff, D. Sheehan. (2010) Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resistance Updates 13:6, 180-195
CrossRef27
&NA;. (2010) Optimization of antifungal therapy is crucial when treating adults with invasive candidiasis in the intensive care unit. Drugs & Therapy Perspectives 26:12, 15-18
CrossRef28
Christopher C Blyth, Katherine Hale, Pamela Palasanthiran, Tracey O'Brien, Michael H Bennett. (2010) Cochrane review: Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Evidence-Based Child Health: A Cochrane Review Journal 5:4, 1916-1998
CrossRef29
Pramodini B Kale-Pradhan, Geoffrey Morgan, Sheila M Wilhelm, Leonard B Johnson. (2010) Comparative Efficacy of Echinocandins and Nonechinocandins for the Treatment of Candida parapsilosis Infections: A Meta-analysis. Pharmacotherapy 30:12, 1207-1213
CrossRef30
Nikolaos G Almyroudis, Brahm H Segal. (2010) Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients. Expert Review of Anti-infective Therapy 8:12, 1451-1466
CrossRef31
Michael A. Pfaller, Daniel J. Diekema. (2010) Wild-Type MIC Distributions and Epidemiologic Cutoff Values for Fluconazole and Candida: Time for New Clinical Breakpoints?. Current Fungal Infection Reports 4:3, 168-174
CrossRef32
Russell E. Lewis. (2010) Antifungal Therapeutic Drug Monitoring. Current Fungal Infection Reports 4:3, 158-167
CrossRef33
2010. Rationale for Biofilm Eradication from Modern Medical Devices. , 36-72.
CrossRef34
2010. Strategies for Prevention of Device-Related Nosocomial Infections. , 265-336.
CrossRef35
D. Neofytos, J.A. Fishman, D. Horn, E. Anaissie, C.-H. Chang, A. Olyaei, M. Pfaller, W.J. Steinbach, K.M. Webster, K.A. Marr. (2010) Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transplant Infectious Disease 12:3, 220-229
CrossRef36
Anna K. Person, Dimitrios P. Kontoyiannis, Barbara D. Alexander. (2010) Fungal Infections in Transplant and Oncology Patients. Infectious Disease Clinics of North America 24:2, 439-459
CrossRef37
A. Glöckner. (2010) Leitliniengerechte Therapie: Candidämie/invasive Candidiasis. Mycoses 53, 30-35
CrossRef38
E. Geoffrey Playford, Jeff Lipman, Tania C. Sorrell. (2010) Management of Invasive Candidiasis in the Intensive Care Unit. Drugs 70:7, 823-839
CrossRef39
David W. Denning, William W. Hope. (2010) Therapy for fungal diseases: opportunities and priorities. Trends in Microbiology 18:5, 195-204
CrossRef40
Harald Seifert, Hilmar Wisplinghoff. 2010. Bloodstream Infection and Endocarditis. .
CrossRef41
Livio Pagano, Morena Caira, Caterina Giovanna Valentini, Brunella Posteraro, Luana Fianchi. (2010) Current therapeutic approaches to fungal infections in immunocompromised hematological patients. Blood Reviews 24:2, 51-61
CrossRef42
M. Ortega, F. Marco, A. Soriano, M. Almela, J. A. Martinez, C. Pitart, J. Mensa. (2010) Candida spp. bloodstream infection: influence of antifungal treatment on outcome. Journal of Antimicrobial Chemotherapy 65:3, 562-568
CrossRef43
Christopher C Blyth, Katherine Hale, Pamela Palasanthiran, Tracey O'Brien, Michael H Bennett, Christopher C Blyth. 2010. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. .
CrossRef44
Cornelia Lass-Flörl. (2010) Invasive fungal infections in pediatric patients: a review focusing on antifungal therapy. Expert Review of Anti-infective Therapy 8:2, 127-135
CrossRef45
P. Eggimann, D. Pittet. (2010) Candidemia e candidosi generalizzata. EMC - Anestesia-Rianimazione 15:2, 1-24
CrossRef46
C. Lichtenstern, S. Swoboda, M. Hirschburger, E. Domann, T. Hoppe-Tichy, M. Winkler, C. Lass-Flörl, M.A. Weigand. (2010) Update: invasive Pilzinfektionen. Der Anaesthesist 59:1, 30-52
CrossRef47
P. G. Pappas, F. P. Silveira, . (2009) Candida in Solid Organ Transplant Recipients. American Journal of Transplantation 9, S173-S179
CrossRef48
Dustin T. Wilson, Richard H. Drew, John R. Perfect. (2009) Antifungal Therapy for Invasive Fungal Diseases in Allogeneic Stem Cell Transplant Recipients: An Update. Mycopathologia 168:6, 313-327
CrossRef49
Luis Ostrosky-Zeichner. (2009) Issues in the design and interpretation of antifungal drug trials in the critically ill. Current Opinion in Infectious Diseases 22:6, 564-567
CrossRef50
Mariano Pennisi, Massimo Antonelli. (2009) Clinical Aspects of Invasive Candidiasis in Critically Ill Patients. Drugs 69:Supplement 1, 21-28
CrossRef51
Andreas Glöckner, Angela Steinbach, Jörg Janne Vehreschild, Oliver A. Cornely. (2009) Treatment of invasive candidiasis with echinocandins. Mycoses 52:6, 476-486
CrossRef52
Marya D. Zilberberg, Andrew F. Shorr. (2009) Fungal Infections in the ICU. Infectious Disease Clinics of North America 23:3, 625-642
CrossRef53
Naoki Aikawa, Shinya Kusachi, Shigeto Oda, Yoshio Takesue, Hideharu Tanaka. (2009) Clinical effects of micafungin, a novel echinocandin antifungal agent, on systemic fungal infections in surgery, emergency, and intensive-care medicine: evaluation using the AKOTT algorithm. Journal of Infection and Chemotherapy 15:4, 219-227
CrossRef54
(2009) Supplement: Trends in invasive Candida infections and their treatment: focus on echinocandins. Current Medical Research and Opinion 25:7, 1729-1762
CrossRef55
Rabih O. Darouiche. (2009) Candida in the ICU. Clinics in Chest Medicine 30:2, 287-293
CrossRef56
José Mensa, Rafael De La Cámara, Enric Carreras, Manuel Cuenca Estrella, José Ángel García Rodríguez, Miguel Gobernado, Juan Picazo, José María Aguado, Miguel Ángel Sanz. (2009) Tratamiento de las infecciones fúngicas en pacientes con neoplasias hematológicas. Medicina Clínica 132:13, 507-521
CrossRef57
Adam T Gerstenblith, Chirag P Shah. (2009) Candida chorioretinitis and endophthalmitis. Expert Review of Ophthalmology 4:2, 187-196
CrossRef58
Angelika Böhme, Markus Ruhnke, Dieter Buchheidt, Oliver A. Cornely, Herrmann Einsele, Ruxandra Enzensberger, Holger Hebart, Werner Heinz, Christian Junghanss, Meinolf Karthaus, William Krüger, Utz Krug, Thomas Kubin, Olaf Penack, Dietmar Reichert, Stefan Reuter, Gerda Silling, Thomas Südhoff, Andrew J. Ullmann, Georg Maschmeyer. (2009) Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Annals of Hematology 88:2, 97-110
CrossRef59
Elliott Geoffrey Playford, Philippe Eggimann, Thierry Calandra. (2008) Antifungals in the ICU. Current Opinion in Infectious Diseases 21:6, 610-619
CrossRef60
William W Hope, Eliane M Billaud, Jodie Lestner, David W Denning. (2008) Therapeutic drug monitoring for triazoles. Current Opinion in Infectious Diseases 21:6, 580-586
CrossRef61
Jesús Guinea, Emilio Bouza. (2008) Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections. Future Microbiology 3:6, 603-615
CrossRef62
Benito Almirante, Javier Pemán. (2008) Tratamiento actual de la candidemia. Papel de anidulafungina. Enfermedades Infecciosas y Microbiología Clínica 26, 21-28
CrossRef63
AMARNATH KATHRESAL, JOSEPH BIUNDO, CHRISTOPHER M. BLAIS, STEPHEN MORSE, EFRAIN REISIN. (2008) A Rare Case of Candida Arthritis in a Hemodialysis Patient. The American Journal of the Medical Sciences 336:5, 437-440
CrossRef64
Wei Yang, Nathan P Wiederhold, Robert O Williams. (2008) Drug delivery strategies for improved azole antifungal action. Expert Opinion on Drug Delivery 5:11, 1199-1216
CrossRef65
Daniel H. Kett, G. Fernando Cubillos. (2008) Anidulafungin in the treatment of patients with invasive candidiasis. International Journal of Antimicrobial Agents 32, S99-S102
CrossRef66
José Mensa, Cristina Pitart, Francesc Marco. (2008) Treatment of critically ill patients with candidemia. International Journal of Antimicrobial Agents 32, S93-S97
CrossRef67
Mark J. DiNubile. (2008) Double‐Blind Active‐Control Trials: Beware the Comparator You Keep. Clinical Infectious Diseases 47:8, 1064-1067
CrossRef68
Eike Hollenbach. (2008) Invasive candidiasis in the ICU: evidence based and on the edge of evidence. Mycoses 51, 25-45
CrossRef69
Zlate Stojanoski, Aleksandra Pivkova, Sonja Genadieva-Stavrik, Lidija Cevreska, Milena Petrovska, Borche Georgievski. (2008) Antifungal Prophylaxis In Hematopoietic Stem Cell Transplant Recipients. Macedonian Journal of Medical Sciences 1:1, 50-58
CrossRef70
Maria J. G. T. Rüping, Jörg J. Vehreschild, Oliver A. Cornely. (2008) Antifungal treatment strategies in high risk patients. Mycoses 51, 46-51
CrossRef71
A. Gafter-Gvili, L. Vidal, E. Goldberg, L. Leibovici, M. Paul. (2008) Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis. Mayo Clinic Proceedings 83:9, 1011-1021
CrossRef72
Amy Chang, Dionissios Neofytos, David Horn. (2008) Candidemia in the 21st century. Future Microbiology 3:4, 463-472
CrossRef73
G. E. Brzankalski, L. K. Najvar, N. P. Wiederhold, R. Bocanegra, A. W. Fothergill, M. G. Rinaldi, T. F. Pattterson, J. R. Graybill. (2008) Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. Journal of Antimicrobial Chemotherapy 62:5, 1094-1100
CrossRef74
C. Lichtenstern, T. H. Nguyen, P. Schemmer, T. Hoppe-Tichy, M. A. Weigand. (2008) Efficacy of caspofungin in invasive candidiasis and candidemia – de-escalation strategy. Mycoses 51:s1, 35-46
CrossRef75
L. J. Worth, C. C. Blyth, D. L. Booth, D. C. M. Kong, D. Marriott, M. Cassumbhoy, J. Ray, M. A. Slavin, J. R. Wilkes. (2008) Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders. Internal Medicine Journal 38:6b, 521-537
CrossRef76
Peter G. Pappas. (2008) The patient with candidemia: Treatment choices and algorithms. Current Fungal Infection Reports 2:2, 112-119
CrossRef77
K. A. Thursky, E. G. Playford, J. F. Seymour, T. C. Sorrell, D. H. Ellis, S. D. Guy, N. Gilroy, J. Chu, D. R. Shaw. (2008) Recommendations for the treatment of established fungal infections. Internal Medicine Journal 38:6b, 496-520
CrossRef78
Solmaz Celebi, Mustafa Hacimustafaoglu, Ozlem Ozdemir, Guven Ozkaya. (2008) Nosocomial candidaemia in children: results of a 9-year study. Mycoses 51:3, 248-257
CrossRef79
Marcio Nucci, John R. Perfect. (2008) When Primary Antifungal Therapy Fails. Clinical Infectious Diseases 46:9, 1426-1433
CrossRef80
Kieren A. Marr. (2008) Editorial Commentary: Aspergillus Galactomannan Index: A Surrogate End Point to Assess Outcome of Therapy?. Clinical Infectious Diseases 46:9, 1423-1425
CrossRef81
M. Ruhnke, K. Hartwig, G. Kofla. (2008) New options for treatment of candidaemia in critically ill patients. Clinical Microbiology and Infection 14:s4, 46-54
CrossRef82
John Mohr, Melissa Johnson, Travis Cooper, James S Lewis, Luis Ostrosky-Zeichner. (2008) Current Options in Antifungal Pharmacotherapy. Pharmacotherapy 28:5, 614-645
CrossRef83
James S Lewis, John R Graybill. (2008) Fungicidal versus Fungistatic: what's in a word?. Expert Opinion on Pharmacotherapy 9:6, 927-935
CrossRef84
R. Colodner, Y. Nuri, B. Chazan, R. Raz. (2008) Community-acquired and hospital-acquired candiduria: comparison of prevalence and clinical characteristics. European Journal of Clinical Microbiology & Infectious Diseases 27:4, 301-305
CrossRef85
John Bennett. (2008) Editorial Commentary: Is Real‐Time Polymerase Chain Reaction Ready for Real Use in Detecting Candidemia?. Clinical Infectious Diseases 46:6, 897-898
CrossRef86
Mario Cruciani, Giovanni Serpelloni. (2008) Management of Candida infections in the adult intensive care unit. Expert Opinion on Pharmacotherapy 9:2, 175-191
CrossRef87
A. Conen, M. Weisser, C. Orasch Jörg, M. Battegay, A. Trampuz, R. Frei, S. Christen, D. Heim, A. Gratwohl, U. Flückiger. (2008) Candida krusei – a serious complication in patients with hematological malignancies: successful treatment with caspofungin. Transplant Infectious Disease 10:1, 66-70
CrossRef88
S.-Y. Ruan, L.-N. Lee, J.-S. Jerng, C.-J. Yu, P.-R. Hsueh. (2008) Candida glabrata fungaemia in intensive care units. Clinical Microbiology and Infection 14:2, 136-140
CrossRef89
Eric J. Bow. (2008) Considerations in the approach to invasive fungal infection in patients with haematological malignancies. British Journal of Haematology 140:2, 133-152
CrossRef90
F. H. J. Van Enckevort, M. G. Netea, A. R. M. M. Hermus, C. G. J. Sweep, J. F. G. M. Meis, J. W. M. Van Der Meer, Bart Jan Kullberg. (2008) Increased susceptibility to systemic candidiasis in interleukin-6 deficient mice 1. Medical Mycology 37:6, 419
CrossRef91
Maria J G T Rüping, Jörg J Vehreschild, Oliver A Cornely. (2008) Patients at High Risk of Invasive Fungal Infections. Drugs 68:14, 1941-1962
CrossRef92
Fida A Khan, Douglas Slain, Rashida A Khakoo. (2007) Candida Endophthalmitis: Focus on Current and Future Antifungal Treatment Options. Pharmacotherapy 27:12, 1711-1721
CrossRef93
Ingi Lee, Theoklis Zaoutis. 2007. Emerging Resistance Among Candida Species: Trends and Treatment Considerations for Candidemia. , 219-230.
CrossRef94
Robert C. Moellering, John R. Graybill, John E. McGowan, Lawrence Corey. (2007) Antimicrobial resistance prevention initiative—an update: Proceedings of an expert panel on resistance. American Journal of Infection Control 35:9, S1-S23
CrossRef95
Olga Delgado Sánchez, Francesc Puigventós Latorre, Manel Pinteño Blanco, Pere Ventayol Bosch. (2007) Equivalencia terapéutica: concepto y niveles de evidencia. Medicina Clínica 129:19, 736-745
CrossRef96
S. Kannangara, D. Shindler, D. Y. Kunimoto, B. Sell, J. A. DeSimone. (2007) Candidemia complicated by endophthalmitis: a prospective analysis. European Journal of Clinical Microbiology & Infectious Diseases 26:11, 839-841
CrossRef97
Christine C Chiou, Thomas J Walsh, Andreas H Groll. (2007) Clinical pharmacology of antifungal agents in pediatric patients. Expert Opinion on Pharmacotherapy 8:15, 2465-2489
CrossRef98
P. G. Pappas, C. M. F. Rotstein, R. F. Betts, M. Nucci, D. Talwar, J. J. De Waele, J. A. Vazquez, B. F. Dupont, D. L. Horn, L. Ostrosky-Zeichner, A. C. Reboli, B. Suh, R. Digumarti, C. Wu, L. L. Kovanda, L. J. Arnold, D. N. Buell. (2007) Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis. Clinical Infectious Diseases 45:7, 883-893
CrossRef99
Scott J. Bergman, Cristian Speil, Michael Short, Janak Koirala. (2007) Pharmacokinetic and Pharmacodynamic Aspects of Antibiotic Use in High-Risk Populations. Infectious Disease Clinics of North America 21:3, 821-846
CrossRef100
M D Johnson, J R Perfect. (2007) Combination antifungal therapy: what can and should we expect?. Bone Marrow Transplantation 40:4, 297-306
CrossRef101
Joshua J Gagne, Neil I Goldfarb. (2007) Candidemia in the in-patient setting: treatment options and economics. Expert Opinion on Pharmacotherapy 8:11, 1643-1650
CrossRef102
Rose Kim, Deborah Khachikian, Annette C Reboli. (2007) A comparative evaluation of properties and clinical efficacy of the echinocandins. Expert Opinion on Pharmacotherapy 8:10, 1479-1492
CrossRef103
Robert C. Moellering, John R. Graybill, John E. McGowan, Lawrence Corey. (2007) Antimicrobial Resistance Prevention Initiative—An Update: Proceedings of an Expert Panel on Resistance. The American Journal of Medicine 120:7, S4-S25
CrossRef104
Raoul Herbrecht, Ursula Flückiger, Bertrand Gachot, Patricia Ribaud, Anne Thiebaut, Catherine Cordonnier. (2007) Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. European Journal of Cancer Supplements 5:2, 49-59
CrossRef105
J. Jensen, P. Munoz, J. Guinea, M. Rodriguez-Creixems, T. Pelaez, E. Bouza. (2007) Mixed Fungemia: Incidence, Risk Factors, and Mortality in a General Hospital. Clinical Infectious Diseases 44:12, e109-e114
CrossRef106
Reboli, Annette C., Rotstein, Coleman, Pappas, Peter G., Chapman, Stanley W., Kett, Daniel H., Kumar, Deepali, Betts, Robert, Wible, Michele, Goldstein, Beth P., Schranz, Jennifer, Krause, David S., Walsh, Thomas J., . (2007) Anidulafungin versus Fluconazole for Invasive Candidiasis. New England Journal of Medicine 356:24, 2472-2482
Full Text107
Sobel, Jack D., Revankar, Sanjay G., . (2007) Echinocandins — First-Choice or First-Line Therapy for Invasive Candidiasis?. New England Journal of Medicine 356:24, 2525-2526
Full Text108
Nathan P Wiederhold, James S Lewis. (2007) The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opinion on Pharmacotherapy 8:8, 1155-1166
CrossRef109
Hua Chen, Katie J. Suda, Robin S. Turpin, Manjunath P. Pai, David T. Bearden, Kevin W. Garey. (2007) High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis. Current Medical Research and Opinion 23:5, 1057-1065
CrossRef110
Meinolf Karthaus, Oliver A. Cornely. (2007) Treatment options in candidaemia. Mycoses 50:s1, 44-49
CrossRef111
John R. Wingard. (2007) New approaches to invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patients. Best Practice & Research Clinical Haematology 20:1, 99-107
CrossRef112
José Miguel Cisneros-Herreros, Javier Cobo-Reinoso, Miquel Pujol-Rojo, Jesús Rodríguez-Baño, Miguel Salavert-Lletí. (2007) Guía para el diagnóstico y tratamiento del paciente con bacteriemia. Guías de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Enfermedades Infecciosas y Microbiología Clínica 25:2, 111-130
CrossRef113
Christopher Blyth, Katherine Hale, Pamela Palasanthiran, Tracey O'Brien, Michael H Bennett, Christopher Blyth. 2007. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. .
CrossRef114
Joshua Perlroth, Bryan Choi, Brad Spellberg. (2007) Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Medical Mycology 45:4, 321-346
CrossRef115
Ralf Bialek, Andreas Groll, Ulrich Heininger, Volker Schuster. 2007. Infektionserkrankungen. , 439-533.
CrossRef116
George A Sarosi. (2006) Fungal infections and their treatment in the intensive care unit. Current Opinion in Internal Medicine 5:6, 553-558
CrossRef117
C. Voigt, H. Lill. (2006) Die Candida-albicans-induzierte Spondylodiszitis der Halswirbelsäule bei einem polytraumatisierten Patienten. Der Unfallchirurg 109:11, 998-1002
CrossRef118
Ruth Matthews, . (2006) Reply to Herbrecht et al.. Clinical Infectious Diseases 43:8, 1083-1084
CrossRef119
Matteo Bassetti, Elda Righi, Mario Tumbarello, Antonio Di Biagio, Raffaella Rosso, Claudio Viscoli. (2006) Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. Expert Review of Anti-infective Therapy 4:5, 875-885
CrossRef120
Helen L. Leather, John R. Wingard. (2006) New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies. Blood Reviews 20:5, 267-287
CrossRef121
Peter G. Pappas. (2006) Invasive Candidiasis. Infectious Disease Clinics of North America 20:3, 485-506
CrossRef122
David Andes. (2006) Pharmacokinetics and Pharmacodynamics of Antifungals. Infectious Disease Clinics of North America 20:3, 679-697
CrossRef123
Pamela A. Lipsett. (2006) Surgical critical care: Fungal infections in surgical patients. Critical Care Medicine 34:Suppl, S215-S224
CrossRef124
Fowler, Vance G. Jr., Boucher, Helen W., Corey, G. Ralph, Abrutyn, Elias, Karchmer, Adolf W., Rupp, Mark E., Levine, Donald P., Chambers, Henry F., Tally, Francis P., Vigliani, Gloria A., Cabell, Christopher H., Link, Arthur Stanley, DeMeyer, Ignace, Filler, Scott G., Zervos, Marcus, Cook, Paul, Parsonnet, Jeffrey, Bernstein, Jack M., Price, Connie Savor, Forrest, Graeme N., Fätkenheuer, Gerd, Gareca, Marcelo, Rehm, Susan J., Brodt, Hans Reinhardt, Tice, Alan, Cosgrove, Sara E., . (2006) Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus. New England Journal of Medicine 355:7, 653-665
Full Text125
Stefan Neuburger, Georg Maschmeyer. (2006) Update on management of infections in cancer and stem cell transplant patients. Annals of Hematology 85:6, 345-356
CrossRef126
Shih-Hung Tsai, Yi-Jen Peng, Ning-Chi Wang. (2006) Pyomyositis with Hepatic and Perinephric Abscesses Caused by Candida albicans in a Diabetic Nephropathy Patient. The American Journal of the Medical Sciences 331:5, 292-294
CrossRef127
Michelle S Turner, Richard H Drew, John R Perfect. (2006) Emerging echinocandins for treatment of invasive fungal infections. Expert Opinion on Emerging Drugs 11:2, 231-250
CrossRef128
W. E. Dismukes. (2006) Antifungal Therapy: Lessons Learned over the Past 27 Years. Clinical Infectious Diseases 42:9, 1289-1296
CrossRef129
Alison R. Saalwachter, Traci Hedrick, Robert G. Sawyer. (2006) The Other Fungi: It's Not Just Candida albicans Anymore. Surgical Infections 7:2, 143-150
CrossRef130
Jerónimo Pachón, José Miguel Cisneros, Antonio Ramón Collado-Romacho, José Manuel Lomas-Cabezas, Fernando Lozano de León-Naranjo, Jorge Parra-Ruiz, Antonio Rivero-Román. (2006) Tratamiento de las infecciones fúngicas invasoras. Enfermedades Infecciosas y Microbiología Clínica 24:4, 254-263
CrossRef131
Barbara D. Alexander, Elizabeth Dodds Ashley, L. Barth Reller, Shelby D. Reed. (2006) Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures. Diagnostic Microbiology and Infectious Disease 54:4, 277-282
CrossRef132
BJ Kullberg, JH Rex, M Ruhnke, JD Sobel, PG Pappas. (2006) Candidaemia secondary to intravascular catheter colonisation? – Authors' reply. The Lancet 367:9512, 729
CrossRef133
Luis Ostrosky-Zeichner, Peter G. Pappas. (2006) Invasive candidiasis in the intensive care unit. Critical Care Medicine 34:3, 857-863
CrossRef134
S. B. Girois, F. Chapuis, E. Decullier, B. G. P. Revol. (2006) Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. European Journal of Clinical Microbiology & Infectious Diseases 25:2, 138-149
CrossRef135
Daniel H Deck, B Joseph Guglielmo. (2006) Pharmacological advances in the treatment of invasive candidiasis. Expert Review of Anti-infective Therapy 4:1, 137-149
CrossRef136
H. Wisplinghoff, H. Seifert, R. P. Wenzel, M. B. Edmond. (2006) Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp.. Clinical Microbiology and Infection 12:2, 170-177
CrossRef137
B. J. Spellberg, S. G. Filler, J. E. Edwards. (2006) Current Treatment Strategies for Disseminated Candidiasis. Clinical Infectious Diseases 42:2, 244-251
CrossRef138
Robert Betts, Axel Glasmacher, Johan Maertens, Georg Maschmeyer, Jose A. Vazquez, Hedy Teppler, Arlene Taylor, Robert Lupinacci, Carole Sable, Nicholas Kartsonis. (2006) Efficacy of caspofungin against invasiveCandida or invasiveAspergillus infections in neutropenic patients. Cancer 106:2, 466-473
CrossRef139
S. M. Arend, E. J. Kuijper, B. J. Vaal, J. W. Fijter, J. W. Wout. (2006) Successful treatment of fungus balls due to fluconazole-resistant Candida sake obstructing ureter stents in a renal transplant patient. European Journal of Clinical Microbiology & Infectious Diseases 25:1, 43-45
CrossRef140
Masahiro Kami, Tomoko Matsumura. (2006) Fungal Infection Following Reduced-Intensity Stem Cell Transplantation (RIST). Nippon Ishinkin Gakkai Zasshi 47:3, 143-153
CrossRef141
Yan-Shen Shan, Edgar D. Sy, Shan-Tair Wang, Jenq-Chang Lee, Pin-Wen Lin. (2006) Early Presumptive Therapy with Fluconazole for Occult Candida Infection after Gastrointestinal Surgery. World Journal of Surgery 30:1, 119-126
CrossRef142
John H. Powers. (2005) Microbiologic Surrogate End Points in Clinical Trials of Infectious Diseases: Example of Acute Otitis Media Trials. Pharmacotherapy 25:12 Part 2, 109S-123S
CrossRef143
Jorge Garbino, Lydia Markham, Raimonda Matulionyte, Vincent Rives, Daniel Lew. (2005) Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes. Scandinavian Journal of Infectious Diseases1-1
CrossRef144
T. E. Zaoutis, J. Argon, J. Chu, J. A. Berlin, T. J. Walsh, C. Feudtner. (2005) The Epidemiology and Attributable Outcomes of Candidemia in Adults and Children Hospitalized in the United States: A Propensity Analysis. Clinical Infectious Diseases 41:9, 1232-1239
CrossRef145
I. Mohammedi, A. Thiebaut, M.A. Piens, L. Argaud, O. Martin, D. Robert. (2005) Emergence of Candida albicans fungemia during voriconazole therapy. Journal of Infection 51:3, e83-e84
CrossRef146
M. Weinberger, L. Leibovici, S. Perez, Z. Samra, I. Ostfeld, I. Levi, E. Bash, D. Turner, A. Goldschmied-Reouven, G. Regev-Yochay, S.D. Pitlik, N. Keller. (2005) Characteristics of candidaemia with Candida-albicans compared with non-albicans Candida species and predictors of mortality. Journal of Hospital Infection 61:2, 146-154
CrossRef147
D. Andes, N. Safdar. (2005) Efficacy of micafungin for the treatment of candidemia. European Journal of Clinical Microbiology & Infectious Diseases 24:10, 662-664
CrossRef148
BJ Kullberg, JD Sobel, M Ruhnke, PG Pappas, C Viscoli, JH Rex, JD Cleary, E Rubinstein, LWP Church, JM Brown, HT Schlamm, IT Oborska, F Hilton, MR Hodges. (2005) Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. The Lancet 366:9495, 1435-1442
CrossRef149
L. Ostrosky-Zeichner, D. Kontoyiannis, J. Raffalli, K. M. Mullane, J. Vazquez, E. J. Anaissie, J. Lipton, P. Jacobs, J. H. Jansen Rensburg, J. H. Rex, W. Lau, D. Facklam, D. N. Buell. (2005) International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. European Journal of Clinical Microbiology & Infectious Diseases 24:10, 654-661
CrossRef150
John R Graybill. (2005) Voriconazole for candidosis: an important addition?. The Lancet 366:9495, 1413-1414
CrossRef151
S. Koch, H. Haefner, F. Huenger, G. Haase, J. Wildberger, S. W. Lemmen. (2005) Diagnostik und Therapie invasiver Pilzinfektionen auf der Intensivstation. Der Anaesthesist 54:10, 1047-1066
CrossRef152
A. Malani, J. Hmoud, L. Chiu, P. L. Carver, A. Bielaczyc, C. A. Kauffman. (2005) Candida glabrata Fungemia: Experience in a Tertiary Care Center. Clinical Infectious Diseases 41:7, 975-981
CrossRef153
G. M. Gauthier, T. M. Nork, R. Prince, D. Andes. (2005) Subtherapeutic Ocular Penetration of Caspofungin and Associated Treatment Failure in Candida albicans Endophthalmitis. Clinical Infectious Diseases 41:3, e27-e28
CrossRef154
Alexandria Garavaglia Wilson, Scott T. Micek, David J. Ritchie. (2005) A retrospective Evaluation of fluconazole for the treatment of Candida glabrata fungemia. Clinical Therapeutics 27:8, 1228-1237
CrossRef155
M. A. Fischer, W. C. Winkelmayer, R. H. Rubin, J. Avorn. (2005) The Hepatotoxicity of Antifungal Medications in Bone Marrow Transplant Recipients. Clinical Infectious Diseases 41:3, 301-307
CrossRef156
P. Brian Smith, William J. Steinbach, Daniel K. Benjamin. (2005) Invasive Candida infections in the neonate. Drug Resistance Updates 8:3, 147-162
CrossRef157
Grzegorz Kofla, Markus Ruhnke. (2005) Voriconazole: review of a broad spectrum triazole antifungal agent. Expert Opinion on Pharmacotherapy 6:7, 1215-1229
CrossRef158
Randall G Fisher, Mitchell Gary Karlowicz, Joel Lall-Trail. (2005) Very Low Prevalence of Endophthalmitis in Very Low Birthweight Infants who Survive Candidemia. Journal of Perinatology 25:6, 408-411
CrossRef159
M. S. Ibelings, K. Maquelin, H. Ph. Endtz, H. A. Bruining, G. J. Puppels. (2005) Rapid identification of Candida spp. in peritonitis patients by Raman spectroscopy. Clinical Microbiology and Infection 11:5, 353-358
CrossRef160
James I. Ito, Roya Hooshmand‐Rad. (2005) Treatment of Candida Infections with Amphotericin B Lipid Complex. Clinical Infectious Diseases 40:S6, S384-S391
CrossRef161
Meinolf Karthaus, Oliver A. Cornely. (2005) Recent developments in the management of invasive fungal infections in patients with hematological malignancies. Annals of Hematology 84:4, 207-216
CrossRef162
K. H. Staubach. (2005) Pilzsepsis - Therapeutische Strategie. Fungal sepsis - therapeutical strategy. Mycoses 48:s1, 72-77
CrossRef163
Chantal Fradin, Piet De Groot, Donna MacCallum, Martin Schaller, Frans Klis, Frank C. Odds, Bernhard Hube. (2005) Granulocytes govern the transcriptional response, morphology and proliferation of Candida albicans in human blood. Molecular Microbiology 56:2, 397-415
CrossRef164
C. Boos, P. Kujath, H. -P. Bruch. (2005) Intraabdominelle Pilzinfektionen. Intra-abdominal mycoses. Mycoses 48:s1, 22-26
CrossRef165
S. B. Girois, F. Chapuis, E. Decullier, B. G. P. Revol. (2005) Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. European Journal of Clinical Microbiology & Infectious Diseases 24:2, 119-130
CrossRef166
M. Kleinberg. (2005) Aspergillosis in the CLEAR outcomes trial: working toward a real-world clinical perspective. Medical Mycology 43:s1, 289-294
CrossRef167
Christof von Eiff, Bernd Jansen, Wolfgang Kohnen, Karsten Becker. (2005) Infections Associated with Medical Devices. Drugs 65:2, 179-214
CrossRef168
Jonathan Cohen, Christian Brun-Buisson, Antoni Torres, James Jorgensen. (2004) Diagnosis of infection in sepsis: An evidence-based review. Critical Care Medicine 32:Supplement, S466-S494
CrossRef169
Juan C. Gea-Banacloche, Steven M. Opal, James Jorgensen, Joseph A. Carcillo, Kent A. Sepkowitz, Catherine Cordonnier. (2004) Sepsis associated with immunosuppressive medications: An evidence-based review. Critical Care Medicine 32:Supplement, S578-S590
CrossRef170
Pierre-Yves Bochud, Marc Bonten, Oscar Marchetti, Thierry Calandra. (2004) Antimicrobial therapy for patients with severe sepsis and septic shock: An evidence-based review. Critical Care Medicine 32:Supplement, S495-S512
CrossRef171
J. H. Powers. (2004) Considerations in Clinical Trials of Combination Antifungal Therapy. Clinical Infectious Diseases 39:Supplement 4, S228-S235
CrossRef172
J. H. Rex, J. R. Wingard, R. Wenzel, R. Herbrecht, J. Sobel, J. E. Edwards. (2004) The Design of Clinical Trials That Evaluate Antifungal Prophylaxis and Combination Therapy: Introduction and Overview. Clinical Infectious Diseases 39:Supplement 4, S165-S169
CrossRef173
J. D. Sobel. (2004) Combination Therapy for Invasive Mycoses: Evaluation of Past Clinical Trial Designs. Clinical Infectious Diseases 39:Supplement 4, S224-S227
CrossRef174
T. Calandra, O. Marchetti. (2004) Clinical Trials of Antifungal Prophylaxis among Patients Undergoing Surgery. Clinical Infectious Diseases 39:Supplement 4, S185-S192
CrossRef175
L. Ostrosky-Zeichner. (2004) Prophylaxis and treatment of invasive candidiasis in the intensive care setting. European Journal of Clinical Microbiology & Infectious Diseases 23:10, 739-744
CrossRef176
R. O. Darouiche. (2004) Echinocandins: Ask Not What They Can Do for Esophageal Candidiasis--Ask What Studies of Esophageal Candidiasis Can Do for Them. Clinical Infectious Diseases 39:6, 850-852
CrossRef177
Michael A Pfaller. (2004) Anidulafungin: an echinocandin antifungal. Expert Opinion on Investigational Drugs 13:9, 1183-1197
CrossRef178
G. Maschmeyer, M. Ruhnke. (2004) Update on antifungal treatment of invasive Candida and Aspergillus infections. Derzeitiger Kenntnisstand in der antimykotischen Behandlung invasiver Candida- und Aspergillus-Infektionen. Mycoses 47:7, 263-276
CrossRef179
Salomon M. Stemmer, Yasmin Maor, Izhar Hardan. (2004) Oral Fluconazole for Empiric Treatment of Prolonged Fever in Neutropenic Patients. American Journal of Clinical Oncology 27:4, 328-332
CrossRef180
Daniel J. Diekema, Michael A. Pfaller. (2004) Nosocomial Candidemia: An Ounce of Prevention Is Better Than a Pound of Cure • . Infection Control and Hospital Epidemiology 25:8, 624-626
CrossRef181
Jong Hee Shin, Mi‐Na Kim, Dong Hyeon Shin, Sook‐In Jung, Kwang Jin Kim, Duck Cho, Seung Jung Kee, Myung Geun Shin, Soon Pal Suh, Dong Wook Ryang. (2004) Genetic Relatedness Among Candida tropicalis Isolates From Sporadic Cases of Fungemia in Two University Hospitals in Korea • . Infection Control and Hospital Epidemiology 25:8, 634-640
CrossRef182
Younes Maaroufi, Jean-Marc De Bruyne, Valérie Duchateau, Aspasia Georgala, Françoise Crokaert. (2004) Early Detection and Identification of Commonly Encountered Candida Species from Simulated Blood Cultures by Using a Real-Time PCR-Based Assay. The Journal of Molecular Diagnostics 6:2, 108-114
CrossRef183
C. J. Crnich, D. G. Maki. (2004) Are Antimicrobial-Impregnated Catheters Effective? Don't Throw Out the Baby with the Bathwater. Clinical Infectious Diseases 38:9, 1287-1292
CrossRef184
Issam Raad, Hend Hanna, Maha Boktour, Essam Girgawy, Hadi Danawi, Masoud Mardani, Dimitrios Kontoyiannis, Rabih Darouiche, Ray Hachem, Gerald P. Bodey. (2004) Management of Central Venous Catheters in Patients with Cancer and Candidemia. Clinical Infectious Diseases 38:8, 1119-1127
CrossRef185
W. W. Hope, D. W. Denning. (2004) Optimising antifungal therapy for individual patients. Internal Medicine Journal 34:4, 147-149
CrossRef186
Zachary A Rubin, Jyoti Somani. (2004) New options for the treatment of invasive fungal infections. Seminars in Oncology 31, 91-98
CrossRef187
Monica Slavin, John Fastenau, Isaya Sukarom, Panagiotis Mavros, Steven Crowley, William C Gerth. (2004) Burden of hospitalization of patients with Candida and Aspergillus infections in Australia. International Journal of Infectious Diseases 8:2, 111-120
CrossRef188
David A. Stevens. (2004) Azoles in the Management of Systemic Fungal Infections. Infectious Diseases in Clinical Practice 12:2, 81-92
CrossRef189
J Ibàñez-Nolla, M Nolla-Salas, M.A León, F Garcı́a, J Marrugat, G Soria, R.M Dı́az, J.M Torres-Rodrı́guez. (2004) Early diagnosis of candidiasis in non-neutropenic critically ill patients. Journal of Infection 48:2, 181-192
CrossRef190
Robert P. Rapp. (2004) Changing Strategies for the Management of Invasive Fungal Infections. Pharmacotherapy 24:2 Part 2, 4S-28S
CrossRef191
Peter G. Pappas, John H. Rex, Jack D. Sobel, Scott G. Filler, William E. Dismukes, Thomas J. Walsh, John E. Edwards. (2004) Guidelines for Treatment of Candidiasis. Clinical Infectious Diseases 38:2, 161-189
CrossRef192
John H. Powers, Renata Albrecht. (2004) Lipid Amphotericin B Formulations as Comparators in Clinical Trials. Clinical Infectious Diseases 38:2, 305-306
CrossRef193
P. Gothard, T. R. Rogers. (2004) Voriconazole for serious fungal infections. International Journal of Clinical Practice 58:1, 74-80
CrossRef194
Stijn Blot, Koenraad Vandewoude. (2004) Management of Invasive Candidiasis in Critically Ill Patients. Drugs 64:19, 2159-2175
CrossRef195
Philippe Eggimann, Jorge Garbino, Didier Pittet. (2003) Management of candidiasis Management of Candida species infections in critically ill patients. The Lancet Infectious Diseases 3:12, 772-785
CrossRef196
Annie Wong-Beringer, Jane Kriengkauykiat. (2003) Systemic Antifungal Therapy: New Options, New Challenges. Pharmacotherapy 23:11, 1441-1462
CrossRef197
Philippe Eggimann, Jorge Garbino, Didier Pittet. (2003) Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. The Lancet Infectious Diseases 3:11, 685-702
CrossRef198
Nina Singh. (2003) Treatment of opportunistic mycoses: how long is long enough?. The Lancet Infectious Diseases 3:11, 703-708
CrossRef199
Shigeru Shibata, Hiroshi Miyakawa, Seiichiro Shimizu, Shunya Uchida. (2003) Fever and anuria. The Lancet 362:9398, 1806
CrossRef200
O. Gudlaugsson, S. Gillespie, K. Lee, J. V. Berg, J. Hu, S. Messer, L. Herwaldt, M. Pfaller, D. Diekema. (2003) Attributable Mortality of Nosocomial Candidemia, Revisited. Clinical Infectious Diseases 37:9, 1172-1177
CrossRef201
Angelika Böhme, Markus Ruhnke, Dieter Buchheidt, Meinolf Karthaus, Hermann Einsele, Stefan Guth, Gudrun Heussel, Claus-Peter Heussel, Christian Junghanss, Winfried K. Kern, Thomas Kubin, Georg Maschmeyer, Orhan Sezer, Gerda Silling, Thomas Südhoff, Hubert Szelényi†, Andrew J. Ullmann. (2003) Treatment of fungal infections in hematology and oncology. Annals of Hematology 82:S2, S133-S140
CrossRef202
David W Denning. (2003) Echinocandin antifungal drugs. The Lancet 362:9390, 1142-1151
CrossRef203
Kalomoira Kollia, Michael Arabatzis, Olga Kostoula, Akrivi Kostourou, Aristea Velegraki, Elina Belessiotou, Aekaterini Lazou, Akrivi Kostourou. (2003) Clavispora (Candida) lusitaniae susceptibility profiles and genetic diversity in three tertiary hospitals (1998–2001). International Journal of Antimicrobial Agents 22:4, 458-460
CrossRef204
P. G. Pappas, J. H. Rex, J. Lee, R. J. Hamill, R. A. Larsen, W. Powderly, C. A. Kauffman, N. Hyslop, J. E. Mangino, S. Chapman, H. W. Horowitz, J. E. Edwards, W. E. Dismukes, . (2003) A Prospective Observational Study of Candidemia: Epidemiology, Therapy, and Influences on Mortality in Hospitalized Adult and Pediatric Patients. Clinical Infectious Diseases 37:5, 634-643
CrossRef205
L. D. Saravolatz, L. Ostrosky-Zeichner, K. A. Marr, J. H. Rex, S. H. Cohen. (2003) Amphotericin B: Time for a New "Gold Standard". Clinical Infectious Diseases 37:3, 415-425
CrossRef206
Nirmala Shanmugam, Rainer Isenmann, Jamie S. Barkin, Hans G. Beger. (2003) Pancreatic Fungal Infection. Pancreas 27:2, 133-138
CrossRef207
John H. Rex, Peter G. Pappas, Adolf W. Karchmer, Jack Sobel, John E. Edwards, Susan Hadley, Corstiaan Brass, Jose A. Vazquez, Stanley W. Chapman, Harold W. Horowitz, Marcus Zervos, David McKinsey, Jeannette Lee, Timothy Babinchak, Robert W. Bradsher, John D. Cleary, David M. Cohen, Larry Danziger, Mitchell Goldman, Jesse Goodman, Eileen Hilton, Newton E. Hyslop, Daniel H. Kett, Jon Lutz, Robert H. Rubin, W. Michael Scheld, Mindy Schuster, Bryan Simmons, David K. Stein, Ronald G. Washburn, Linda Mautner, Teng‐Chiao Chu, Helene Panzer, Rebecca B. Rosenstein, Jenia Booth, . (2003) A Randomized and Blinded Multicenter Trial of High‐Dose Fluconazole plus Placebo versus Fluconazole plus Amphotericin B as Therapy for Candidemia and Its Consequences in Nonneutropenic Subjects. Clinical Infectious Diseases 36:10, 1221-1228
CrossRef208
Libsen J. Rodríguez-Adrián, Robert T. King, Luis G. Tamayo-Derat, John W. Miller, Charles A. Garcia, John H. Rex. (2003) Retinal Lesions as Clues to Disseminated Bacterial and Candidal Infections. Medicine 82:3, 187-202
CrossRef209
John R. Perfect, Kieren A. Marr, Thomas J. Walsh, Richard N. Greenberg, Bertrand DuPont, Julian de la Torre‐Cisneros, Gudrun Just‐Nubling, Haran T Schlamm, Irja Lutsar, Ana Espinel‐Ingroff, Elizabeth Johnson. (2003) Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections. Clinical Infectious Diseases 36:9, 1122-1131
CrossRef210
David W Denning, Christopher C Kibbler, Rosemary A Barnes. (2003) British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. The Lancet Infectious Diseases 3:4, 230-240
CrossRef211
D.P. Kontoyiannis, E. Mantadakis, G. Samonis. (2003) Systemic mycoses in the immunocompromised host: an update in antifungal therapy. Journal of Hospital Infection 53:4, 243-258
CrossRef212
(2003) Caspofungin versus Amphotericin B for Invasive Candidiasis. New England Journal of Medicine 348:13, 1287-1288
Full Text213
Andreas H Groll, Juan C Gea-Banacloche, Axel Glasmacher, Gudrun Just-Nuebling, Georg Maschmeyer, Thomas J Walsh. (2003) Clinical pharmacology of antifungal compounds. Infectious Disease Clinics of North America 17:1, 159-191
CrossRef214
Wolfram Trudo Knoefel. (2003) Is prediction imperative before prevention? *. Critical Care Medicine 31:3, 976-977
CrossRef215
William J. Steinbach, John R. Perfect. (2003) Newer antifungal therapy for emerging fungal pathogens. International Journal of Infectious Diseases 7:1, 5-20
CrossRef216
J. Loeffler, D. A. Stevens. (2003) Antifungal Drug Resistance. Clinical Infectious Diseases 36:Supplement 1, S31-S41
CrossRef217
Mora-Duarte, Jorge, Betts, Robert, Rotstein, Coleman, Colombo, Arnaldo Lopes, Thompson-Moya, Luis, Smietana, Juanita, Lupinacci, Robert, Sable, Carole, Kartsonis, Nicholas, Perfect, John, . (2002) Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis. New England Journal of Medicine 347:25, 2020-2029
Full Text218
Brahm H Segal, Eric J Bow, Francisco Menichetti. (2002) Fungal infections in nontransplant patients with hematologic malignancies. Infectious Disease Clinics of North America 16:4, 935-964
CrossRef219
JORGE GARBINO, LENKA KOLAROVA, PETER ROHNER, DANIEL LEW, PETER PICHNA, DIDIER PITTET. (2002) Secular Trends of Candidemia Over 12 Years in Adult Patients at a Tertiary Care Hospital. Medicine 81:6, 425-433
CrossRef220
Patricia Muñoz, Cristina Pérez Fernández-Turégano, Luis Alcalá, Marta Rodrı́guez-Créixems, Teresa Peláez, Emilio Bouza. (2002) Frequency and clinical significance of bloodstream infections caused by C. albicans strains with reduced susceptibility to fluconazole. Diagnostic Microbiology and Infectious Disease 44:2, 163-167
CrossRef221
G. Fatkenheuer, O. Cornely, H. Seifert. (2002) Clinical management of catheter-related infections. Clinical Microbiology and Infection 8:9, 545-550
CrossRef222
Brad Spellberg, John E. Edwards. (2002) The pathophysiology and treatment of Candida sepsis. Current Infectious Disease Reports 4:5, 387-399
CrossRef223
Susan Hadley, Winnie W. Lee, Robin Ruthazer, Stanley A. Nasraway. (2002) Candidemia as a cause of septic shock and multiple organ failure in nonimmunocompromised patients. Critical Care Medicine 30:8, 1808-1814
CrossRef224
J. A. Paiva, J. M. Pereira. (2002) Treatment of the afebrile patient after catheter withdrawal: drugs and duration. Clinical Microbiology and Infection 8:5, 290-294
CrossRef225
J. Rodriguez-Bano. (2002) Selection of empiric therapy in patients with catheter-related infections. Clinical Microbiology and Infection 8:5, 275-281
CrossRef226
Pamela A. Lipsett. (2002) Fungal Infections in Surgical Patients. Problems in General Surgery 19:1, 92-102
CrossRef227
M. Nucci, E. Anaissie. (2002) Should Vascular Catheters Be Removed from All Patients with Candidemia? An Evidence-Based Review. Clinical Infectious Diseases 34:5, 591-599
CrossRef228
Walsh, Thomas J., Pappas, Peter, Winston, Drew J., Lazarus, Hillard M., Petersen, Finn, Raffalli, John, Yanovich, Saul, Stiff, Patrick, Greenberg, Richard, Donowitz, Gerald, Schuster, Mindy, Reboli, Annette, Wingard, John, Arndt, Carola, Reinhardt, John, Hadley, Susan, Finberg, Robert, Laverdière, Michél, Perfect, John, Garber, Gary, Fioritoni, Giuseppe, Anaissie, Eli, Lee, Jeanette, . (2002) Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever. New England Journal of Medicine 346:4, 225-234
Full Text229
P Abgueguen, J.P Gouello, E Pichard, D Chabasse, E Donal, P Alquier. (2002) Endocardites à Candida : étude rétrospective de 12 patients. La Revue de Médecine Interne 23:1, 30-40
CrossRef230
Michael A. Pfaller, Wen Liang Yu. (2001) ANTIFUNGAL SUSCEPTIBILITY TESTING. Infectious Disease Clinics of North America 15:4, 1227-1261
CrossRef231
P. Miailhes, M. Labetoulle, T. Naas, M. Guibert, P. Bouree, E. Frau, P. Nordmann, P. Galanaud. (2001) Unusual etiology of visual loss in an HIV-infected patient due to endogenous endophthalmitis. Clinical Microbiology and Infection 7:11, 641-645
CrossRef232
David W. Bates, Ling Su, Donghui T. Yu, Glenn M. Chertow, Diane L. Seger, Daniel R.J. Gomes, Richard Platt. (2001) Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney International 60:4, 1452-1459
CrossRef233
William M. Wind, Brian E. McGrath, Eugene R. Mindell. (2001) Infection following knee arthroscopy. Arthroscopy: The Journal of Arthroscopic & Related Surgery 17:8, 878-883
CrossRef234
Corrado Girmenia, Giuseppe Gentile, Alessandra Micozzi, Pietro Martino. (2001) Nephrotoxicity of Amphotericin B Desoxycholate. Clinical Infectious Diseases 33:6, 915-916
CrossRef235
Dimitrios P. Kontoyiannis. (2001) A Clinical Perspective for the Management of Invasive Fungal Infections: Focus on IDSA Guidelines. Pharmacotherapy 21:8 Part 2, 175S-187S
CrossRef236
Holly L. Hoffman, Michael A. Pfaller. (2001) In Vitro Antifungal Susceptibility Testing. Pharmacotherapy 21:8 Part 2, 111S-123S
CrossRef237
Thomas R. Rogers. (2001) Optimal use of existing and new antifungal drugs. Current Opinion in Critical Care 7:4, 238-241
CrossRef238
N. Singh. (2001) Changing spectrum of invasive candidiasis and its therapeutic implications. Clinical Microbiology and Infection 7:s2, 1-7
CrossRef239
John H. Rex, Thomas J. Walsh, Mary Nettleman, Elias J. Anaissie, John E. Bennett, Eric J. Bow, A. J. Carillo‐Munoz, Pascal Chavanet, Gretchen A. Cloud, David W. Denning, Ben E. de Pauw, John E. Edwards Jr., John W. Hiemenz, Carol A. Kauffman, Gabriel Lopez‐Berestein, Pietro Martino, Jack D. Sobel, David A. Stevens, Richard Sylvester, Jan Tollemar, Claudio Viscoli, Maria A. Viviani, Teresa Wu. (2001) Need for Alternative Trial Designs and Evaluation Strategies for Therapeutic Studies of Invasive Mycoses. Clinical Infectious Diseases 33:1, 95-106
CrossRef240
D. P. Kontoyiannis, G. P. Bodey, C. S. Mantzoros. (2001) Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis. Mycoses 44:5, 125-135
CrossRef241
J. Lopez, C. Pernot, S. Aho, D. Caillot, O. Vagner, F. Dalle, M-J. Durnet-Archeray, P. Chavanet, A. Bonnin. (2001) Decrease in Candida albicans strains with reduced susceptibility to fluconazole following changes in prescribing policies. Journal of Hospital Infection 48:2, 122-128
CrossRef242
S Yang. (2001) Staged reimplantation of total knee arthroplasty after Candida infection. The Journal of Arthroplasty 16:4, 529-532
CrossRef243
Jay I. Peters, Stephanie M. Levine. (2001) Fungal Infection in the Lung Transplant Recipient. Clinical Pulmonary Medicine 8:3, 123-133
CrossRef244
L. A. Mermel, B. M. Farr, R. J. Sherertz, I. I. Raad, N. O'Grady, J. S. Harris, D. E. Craven. (2001) Guidelines for the Management of Intravascular Catheter-Related Infections. Clinical Infectious Diseases 32:9, 1249-1272
CrossRef245
S. Blot, K. Vandewoude, E. Hoste, J. Poelaert, F. Colardyn. (2001) Outcome in critically ill patients with candidal fungaemia: Candida albicans vs. Candida glabrata. Journal of Hospital Infection 47:4, 308-313
CrossRef246
Leonard A. Mermel, Barry M. Farr, Robert J. Sherertz, Issam I. Raad, Naomi O’Grady, JoAnn S. Harris, Donald E. Craven. (2001) Guidelines for the Management of Intravascular Catheter‐Related Infections • . Infection Control and Hospital Epidemiology 22:4, 222-242
CrossRef247
UNKNOWN. (2001) Full Length Article. Annales Françaises d’Anesthésie et de Réanimation 20:4, 382-388
CrossRef248
Stewart G. Albert, Mary Jeanne DeLeon, Alan B. Silverberg. (2001) Possible association between high-dose fluconazole and adrenal insufficiency in critically ill patients. Critical Care Medicine 29:3, 668-670
CrossRef249
J. Maertens, M. Vrebos, M. Boogaerts. (2001) Assessing risk factors for systemic fungal infections. European Journal of Cancer Care 10:1, 56-62
CrossRef250
Ian M. Hann, H.Grant Prentice. (2001) Lipid-based amphotericin B: a review of the last 10 years of use. International Journal of Antimicrobial Agents 17:3, 161-169
CrossRef251
D. W. Bates, L. Su, D. T. Yu, G. M. Chertow, D. L. Seger, D. R. J. Gomes, E. J. Dasbach, R. Platt. (2001) Mortality and Costs of Acute Renal Failure Associated with Amphotericin B Therapy. Clinical Infectious Diseases 32:5, 686-693
CrossRef252
Debra D. Poutsiaka. (2001) Antimicrobial Resistance in the Chronically Critically Ill Patient. Clinics in Chest Medicine 22:1, 87-103
CrossRef253
L. Hendrickx, E. Van Wijngaerden, I. Samson, W. E. Peetermans. (2001) Candidal Vertebral Osteomyelitis: Report of 6 Patients, and a Review. Clinical Infectious Diseases 32:4, 527-533
CrossRef254
E Andrès, M Tiphine, V Letscher-Bru, R Herbrecht. (2001) Nouvelles formes lipidiques de l’amphotéricine B. Revue de la littérature. La Revue de Médecine Interne 22:2, 141-150
CrossRef255
A. Minari, R. Hachem, I. Raad. (2001) Candida lusitaniae: A Cause of Breakthrough Fungemia in Cancer Patients. Clinical Infectious Diseases 32:2, 186-190
CrossRef256
Carol A. Kauffman, Sara A. Hedderwick. (2001) Treatment of Systemic Fungal Infections in Older Patients. Drugs & Aging 18:5, 313-323
CrossRef257
Jasjit Singh, Bill Burr, Del Stringham, Antonio Arrieta. (2001) Commonly Used Antibacterial and Antifungal Agents for Hospitalised Paediatric Patients. Paediatric Drugs 3:10, 733-761
CrossRef258
Rosemary A. Barnes. (2000) Approaches to antifungal therapy in the intensive care unit. Current Opinion in Infectious Diseases 13:6, 609-614
CrossRef259
John F. Fisher. (2000) Candiduria: When and how to treat it. Current Infectious Disease Reports 2:6, 523-530
CrossRef260
Thomas F. Patterson. (2000) Current and future approaches to antifungal therapy. Current Opinion in Infectious Diseases 13:6, 579-561
CrossRef261
Elizabeth S. Dodds, Richard H. Drew, John R. Perfect. (2000) Antifungal Pharmacodynamics: Review of the Literature and Clinical Applications. Pharmacotherapy 20:11, 1335-1355
CrossRef262
M Aoun. (2000) Standard antifungal therapy in neutropenic patients. International Journal of Antimicrobial Agents 16:2, 143-145
CrossRef263
Jack D. Sobel. (2000) Management of infections caused by Candida glabrata. Current Infectious Disease Reports 2:5, 424-428
CrossRef264
Ben E De Pauw. (2000) New antifungal agents and preparations. International Journal of Antimicrobial Agents 16:2, 147-150
CrossRef265
Peter Linden, Penny Williams, Kevin M Chan. (2000) Efficacy and safety of Amphotericin B Lipid Complex Injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clinical Transplantation 14:4, 329-339
CrossRef266
M. J. DiNubile. (2000) Skepticism: A Lost Clinical Art. Clinical Infectious Diseases 31:2, 513-518
CrossRef267
Patricia Muñoz, Almudena Burillo, Emilio Bouza. (2000) Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit. International Journal of Antimicrobial Agents 15:2, 83-90
CrossRef268
J. Strahilevitz, A.M. Sugar, D. Engelhard. (2000) Fluconazole in transplant recipients: options and limitations. Transplant Infectious Disease 2:2, 62-71
CrossRef269
J. H. Rex, T. J. Walsh, J. D. Sobel, S. G. Filler, P. G. Pappas, W. E. Dismukes, J. E. Edwards. (2000) Practice Guidelines for the Treatment of Candidiasis. Clinical Infectious Diseases 30:4, 662-678
CrossRef270
S Rayatt. (2000) Fluconazole use in burns patients. Burns 26:1, 109-110
CrossRef271
Abinash Virk, James M. Steckelberg. (2000) Clinical Aspects of Antimicrobial Resistance. Mayo Clinic Proceedings 75:2, 200-214
CrossRef272
A Virk, J M Steckelberg. (2000) Clinical aspects of antimicrobial resistance.. Mayo Clinic Proceedings 75:2, 200-214
CrossRef273
David S. Burgess, Rhonda W. Hastings, Kimberly K. Summers, Thomas C. Hardin, Michael G. Rinaldi. (2000) Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans
. Diagnostic Microbiology and Infectious Disease 36:1, 13-18
CrossRef274
B.A. Oppenheim. (2000) Optimal Management of Central Venous Catheter-related Infections—What is the Evidence?*. Journal of Infection 40:1, 26-30
CrossRef275
Rohit Krishna, Donald Amuh, Careen Y Lowder, Steven M Gordon, Karim A Adal, Geraldine Hall. (2000) Should all patients with candidaemia have an ophthalmic examination to rule out ocular candidiasis?. Eye 14:1, 30-34
CrossRef276
Vladimı́r Krčméry, Gabriela Kovačičová. (2000) Longitudinal 10-year prospective survey of fungaemia in Slovak Republic: trends in etiology in 310 episodes
CrossRef277
M. Tiphine, V. Letscher-Bru, R. Herbrecht. (1999) Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transplant Infectious Disease 1:4, 273-283
CrossRef278
F. H. J. Van Enckevort, M. G. Netea, A. R. M. M. Hermus, C. G. J. Sweep, J. F. G. M. Meis, J. W. M. Van Der Meer, Bart Jan Kullberg. (1999) Increased susceptibility to systemic candidiasis in interleukin-6 deficient mice 1. Medical Mycology 37:6, 419-426
CrossRef279
Bart Jan Kullberg, Mihai G Netea, Alieke G Vonk, Jos W.M Meer. (1999) Modulation of neutrophil function in host defense against disseminated Candida albicans infection in mice. FEMS Immunology & Medical Microbiology 26:3-4, 299-307
CrossRef280
Carl J. Fichtenbaum, Matthew German, W. Claiborne Dunagan, Victoria J. Fraser, Gerald Medoff, Jorge Diego, William G. Powderly. (1999) A Pilot Study of the Management of Uncomplicated Candidemia with a Standardized Protocol of Amphotericin B. Clinical Infectious Diseases 29:6, 1551-1556
CrossRef281
Magn??s Gottfredsson, John R. Perfect. (1999) Use of antifungal agents in the intensive care unit. Current Opinion in Critical Care 5:5, 381-390
CrossRef282
Roderick J. Hay Md. (1999) New developments in antifungals. International Journal of Dermatology 38:S2, 65-69
CrossRef283
Arnaldo Lopes Colombo, Marcio Nucci, Reinaldo Salomão, Maria Luiza M Branchini, Rosana Richtmann, Andrea Derossi, Sergio B Wey. (1999) High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagnostic Microbiology and Infectious Disease 34:4, 281-286
CrossRef284
Jorg Michael Schierholz, Gerhard Pulverer, Alfons Bach, Zofia Wachol-Drebeck. (1999) In Vitro Activity of Rifampin-Minocyclin Coating to Candida albicans. Critical Care Medicine 27:8, 1691-1692
CrossRef285
Cristiana M. Toscano, William R. Jarvis. (1999) Emerging issues in nosocomial fungal infections. Current Infectious Disease Reports 1:4, 347-361
CrossRef286
Peter G. Pappas, John H. Rex. (1999) Therapeutic approach to Candida sepsis. Current Infectious Disease Reports 1:3, 245-250
CrossRef287
Livio Pagano, Andrea Antinori, Adriana Ammassari, Luca Mele, Annamaria Nosari, Lorella Melillo, Bruno Martino, Maurizio Sanguinetti, Francesco Equitani, Francesco Nobile, Mario Carotenuto, Enrica Morra, Giulia Morace, Giuseppe Leone. (1999) Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes. European Journal of Haematology 63:2, 77-85
CrossRef288
Frans M. Verduyn Lunel, Jacques F.G.M. Meis, Andreas Voss. (1999) Nosocomial fungal infections: candidemia. Diagnostic Microbiology and Infectious Disease 34:3, 213-220
CrossRef289
R.J. Hay. (1999) Lipid amphotericin B combinations; ‘la crème de la créme’?. Journal of Infection 39:1, 16-20
CrossRef290
John H. Rex, Jack D. Sobel. (1999) Preventing intra-abdominal candidiasis in surgical patients. Critical Care Medicine 27:6, 1033-1034
CrossRef291
Andreas Voss. (1999) Therapeutic approach to the patient with candidemia. Clinical Microbiology and Infection 5, 2s51-2s57
CrossRef292
David R. Bristol. (1999) CLINICAL EQUIVALENCE. Journal of Biopharmaceutical Statistics 9:4, 549-561
CrossRef293
Claudio Viscoli, Elio Castagnola. (1999) Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin b in the treatment of fungal infections in cancer patients: A review. International Journal of Infectious Diseases 3:2, 109-118
CrossRef294
D.L. Turner, S.A. Johnson, S.A. Rule. (1999) Successful treatment of candidal osteomyelitis with fluconazole following failure with liposomal amphotericin B. Journal of Infection 38:1, 51-53
CrossRef295
C L Terrell. (1999) Antifungal agents. Part II. The azoles.. Mayo Clinic Proceedings 74:1, 78-100
CrossRef296
R Patel. (1998) Antifungal agents. Part I. Amphotericin B preparations and flucytosine.. Mayo Clinic Proceedings 73:12, 1205-1225
CrossRef297
M.A Pfaller, S.A Messer, A Bolmström. (1998) Evaluation of etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagnostic Microbiology and Infectious Disease 32:3, 223-227
CrossRef298
MÁRIA HUTTOVA, IVETA HARTMANOVA, KAROL KRALINSKY, JOZEF FILKA, JOZEF UHER, JOZEF KURAK, STANISLAV KRIZAN, VLADIMIR KRCMERY. (1998) Candida fungemia in neonates treated with fluconazole: report of forty cases, including eight with meningitis. The Pediatric Infectious Disease Journal 17:11, 1012-1015
CrossRef299
A. Penk und L. Pittrow. (1998) Der Stellenwert von Fluconazol in der Therapie der endogenen Candida -Endophthalmitis. Mycoses 41, 41-44
CrossRef300
Pontus Harten, Bärbel Seyfarth, Norbert Schmitz. (1998) Febrile Neutropenie: Praktische Aspekte. Medizinische Klinik 93:10, 598-611
CrossRef301
A. Wildfeuer, H. P. Seidl, I. Paule, A. Haberreiter. (1998) In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses 41:7-8, 309-319
CrossRef302
J. M. Calvo Romero, J. L.
lvarez Vega, J. M. Salazar Vallinas, R. Ortega Alberdi. (1998) Candida arthritis in an immunocompetent patient without predisposing factors. Clinical Rheumatology 17:5, 393-394
CrossRef303
, Wolfgang Kern, Gerhard Behre, Thomas Rudolf, Andrea Kerkhoff, Albert Grote-Metke, Hartmut Eimermacher, Ursula Kubica, Bernhard W
CrossRef304
P AMBROSE, R OWENSJR, R QUINTILIANI, N YESTON, H CROWE, B CUNHA, C NIGHTINGALE. (1998) ANTIBIOTIC USE IN THE CRITICAL CARE UNIT. Critical Care Clinics 14:2, 283-308
CrossRef305
Issam Raad. (1998) Intravascular-catheter-related infections. The Lancet 351:9106, 893-898
CrossRef306
J. L. Vincent, E. Anaissie, H. Bruining, W. Demajo, M. El-Ebiary, J. Haber, Y. Hiramatsu, G. Nitenberg, P. O. Nyström, D. Pittet, T. Rogers, P. Sandven, G. Sganga, M. D. Schaller, J. Solomkin. (1998) Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Medicine 24:3, 206-216
CrossRef307
I. Stratov, T. Gottlieb, R. Bradbury, G.M. O'Kane. (1998) Candidaemia in an Australian teaching hospital: Relationship to central line and TPN use. Journal of Infection 36:2, 203-207
CrossRef308
P.G. Flanagan, R.A. Barnes. (1998) Fungal infection in the intensive care unit. Journal of Hospital Infection 38:3, 163-177
CrossRef309
David Landman, Guillermo Saurina, John M. Quale. (1998) Failure of All Antifungal Therapy for Infection Due to Candida albicans . A New AIDS‐Related Problem?. Clinical Infectious Diseases 26:1, 183-184
CrossRef310
A. Wildfeuer, H. Laufen, A. F. Schmalreck, R. A. Yeates, T. Zimmermann. (1997) Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility. Mycoses 40:7-8, 259-265
CrossRef311
M. Hacimustafaoglu, B. Ener, Ö Tarim, Ş Killç, A. Tanntanir, I. Ildirim. (1997) Systemic candidiasis with acute Epstein-Barr virus infection. Acta Paediatrica 86:11, 1267-1270
CrossRef312
P.G. Flanagan, R.A. Barnes. (1997) Hazards of inadequate fluconazole dosage to treat deep-seated or systemic Candida albicans infection. Journal of Infection 35:3, 295-297
CrossRef313
Deborah J. Cook, Paul C. Hebert, Daren K. Heyland, Gordon H. Guyatt, Christian Brun-Buisson, John C. Marshall, James Russell, Jean-Louis Vincent, Charles L. Sprung, Frank Rutledge. (1997) How to use an article on therapy or prevention. Critical Care Medicine 25:9, 1502-1513
CrossRef314
G. Carrega, G. Riccio, L. Santoriello, M. Pasqualini, R. Pellicci. (1997) Candida famata fungemia in a surgical patient successfully treated with fluconazole. European Journal of Clinical Microbiology & Infectious Diseases 16:9, 698-699
CrossRef315
Yigal Koltin, Christopher A Hitchcock. (1997) The search for new triazole antifungal agents. Current Opinion in Chemical Biology 1:2, 176-182
CrossRef316
M. E. Bougnoux, C. Dupont, L. Turner, E. Rouveix, M. Dorra, M. H. Nicolas-Chanoine. (1997) MixedCandida glabrata andCandida albicans disseminated candidiasis in a heroin addict. European Journal of Clinical Microbiology & Infectious Diseases 16:8, 598-600
CrossRef317
Pascal Chavanet, Claudine Clement, Michel Duong, Marielle Buisson, Philippe D'Athis, Monique Dumas, Alain Bonnin, Henri Portier. (1997) Toxicity and efficacy of conventional amphotericin B deoxycholate versus escalating doses of amphotericin B deoxycholate-fat emulsion in HIV-infected patients with oral candidosis. Clinical Microbiology and Infection 3:4, 455-461
CrossRef318
B. Beović, T. Lejko-Zupanc, J. Pretnar. (1997) Sequential treatment of deep fungal infections with amphotericin B deoxycholate and amphotericin B colloidal dispersion. European Journal of Clinical Microbiology & Infectious Diseases 16:7, 507-511
CrossRef319
A. S. Rosemurgy, E. E. Zervos, J. F. Sweeney, J. Y. Djeu. (1997) Candida antigen titre dilution and death after injury. British Journal of Surgery 84:6, 771-774
CrossRef320
Wycliffe L. Wright, Richard P. Wenzel. (1997) NOSOCOMIAL CANDIDA. Infectious Disease Clinics of North America 11:2, 411-425
CrossRef321
Mary H. White. (1997) Editorial Response: The Contribution of Fluconazole to the Changing Epidemiology of Invasive Candidal Infections. Clinical Infectious Diseases 24:6, 1129-1130
CrossRef322
P. Phillips, S. Shafran, G. Garber, C. Rotstein, F. Smaill, I. Fong, I. Salit, M. Miller, K. Williams, J. M. Conly, J. Singer, S. Ioannou, . (1997) Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. European Journal of Clinical Microbiology & Infectious Diseases 16:5, 337-345
CrossRef323
C. M. Rieder-Nelissen, J. Hasse, R. A. Yeates, E. Sarnow. (1997) Fluconazole concentrations in pulmonary tissue and pericardial fluid. Infection 25:3, 192-194
CrossRef324
P. F. Troke, . (1997) Large-scale multicentre study of fluconazole in the treatment of hospitalised patients with fungal infections. European Journal of Clinical Microbiology & Infectious Diseases 16:4, 287-295
CrossRef325
D. W. Denning, G. G. Baily, S. V. Hood. (1997) Azole resistance inCandida. European Journal of Clinical Microbiology & Infectious Diseases 16:4, 261-280
CrossRef326
G. Weers-Pothoff, J. F. Havermans, J. Kamphuis, H. A. M. Sinnige, J. F. G. M. Meis. (1997) Candida tropicalis arthritis in a patient with acute myeloid leukemia successfully treated with fluconazole: Case report and review of the literature. Infection 25:2, 109-111
CrossRef327
K. Kralovicova, S. Spanik, E. Oravcova, M. Mrazova, E. Morova, V. Gulikova, E. Kukuckova, P. Koren, P. Pichna, J. Nogova, A. Kunova, J. Trupl, V. Krcmery. (1997) Fungemia in Cancer Patients Undergoing Chemotherapy Versus Surgery: Risk Factors, Etiology and Outcome. Scandinavian Journal of Infectious Diseases 29:3, 301-304
CrossRef328
R. Herbrecht. (1997) Safety of amphotericin B colloidal dispersion. European Journal of Clinical Microbiology & Infectious Diseases 16:1, 74-80
CrossRef329
M.B. Kurtz, C.M. Douglas. (1997) Lipopeptide inhibitors of fungal glucan synthase. Medical Mycology 35:2, 79-86
CrossRef330
Joseph S. Solomkin. (1996) Timing of treatment for nonneutropenic patients colonized with Candida. The American Journal of Surgery 172:6, 44s-48s
CrossRef331
Kelli M. Bullard, David L. Dunn. (1996) Diagnosis and treatment of bacteremia and intravascular catheter infections. The American Journal of Surgery 172:6, 13s-19s
CrossRef332
Scott F. Davies, George A. Sarosi. (1996) FUNGAL PULMONARY COMPLICATIONS. Clinics in Chest Medicine 17:4, 725-744
CrossRef333
Kunio Yano, Shinya Fujisawa, Hirotaka Matsui, Yukio Yamamoto, Kazunari Iijima, Yasuyuki Nakano. (1996) Emergence of nonalbicansCandida species in immunocompromised leukemia patients during fluconazole treatment. Journal of Infection and Chemotherapy 2:4, 268-270
CrossRef334
Mats Kalin, BJÖRN Petrini. (1996) Clinical and laboratory diagnosis of invasive Candida infection in neutropenic patients. Medical Oncology 13:4, 223-231
CrossRef335
David A. Stevens, Julie A. Stevens. (1996) Cross-resistance phenotypes of fluconazole-resistant Candida species: Results with 655 clinical isolates with different methods. Diagnostic Microbiology and Infectious Disease 26:3-4, 145-148
CrossRef336
Marianne Abele-Horn, A. Kopp, U. Sternberg, A. Ohly, O. Nagengast, A. Dauber, W. Russwurm, W. Büchinger, P. Emmerling. (1996) A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemicCandida infections in intensive care patients. Infection 24:6, 426-432
CrossRef337
Lawrence N. Diebel, Anl M. Raafat, Scott A. Dulchavsky, William J. Brown. (1996) Gallbladder and biliary tract candidiasis. Surgery 120:4, 760-765
CrossRef338
D. Law, C.B. Moore, L.A. Joseph, M.G.L. Keaney, D.W. Denning. (1996) High incidence of antifungal drug resistance in Candida tropicalis. International Journal of Antimicrobial Agents 7:4, 241-245
CrossRef339
A. Wildfeuer, H. Laufen, A.-F. Schmalreck, R. A. Yeates, T. Zimmermann. (1996) Fluconazol: Vergleich von Pharmakokinetik, Therapie und Empfindlichkeit der Sproßpilze in vitro. Mycoses 39, 51-57
CrossRef340
C Hennequin. (1996) Épidémiologie des mycoses invasives. L'expérience d'un centre hospitalo-universitaire parisien. La Revue de Médecine Interne 17:9, 754-760
CrossRef341
A. Michalopoulos, S. Geroulanos. (1996) Central venous catheter-related infections. European Journal of Anaesthesiology 13:5, 445-455
CrossRef342
J. Nolla-Salas, A. Sitges-Serra, C. León, M. V. Torre, H. Sancho. (1996) Candida endophthalmitis in non-neutropenic critically ill patients. European Journal of Clinical Microbiology & Infectious Diseases 15:6, 503-506
CrossRef343
V. Krcmery. (1996) Emerging fungal infections in cancer patients. Journal of Hospital Infection 33:2, 109-117
CrossRef344
John N. Greene. (1996) CATHETER-RELATED COMPLICATIONS OF CANCER THERAPY. Infectious Disease Clinics of North America 10:2, 255-295
CrossRef345
F. Dronda, M. Alonso-Sanz, F. Laguna, F. Chaves, J. V. Martínez-Suárez, J. L. Rodríguez-Tudela, A. González-López, E. Valencia. (1996) Mixed oropharyngeal candidiasis due toCandida albicans and non-albicans Candida strains in HIV-infected patients. European Journal of Clinical Microbiology & Infectious Diseases 15:6, 446-452
CrossRef346
R. Herbrecht. (1996) The changing epidemiology of fungal infections: are the lipid-based forms of amphotericin B an advance?. European Journal of Haematology 56:S57, 12-17
CrossRef347
Thomas J. Walsh, John W. Hiemenz, Elias Anaissie. (1996) RECENT PROGRESS AND CURRENT PROBLEMS IN TREATMENT OF INVASIVE FUNGAL INFECTIONS IN NEUTROPENIC PATIENTS. Infectious Disease Clinics of North America 10:2, 365-400
CrossRef348
J. W. Wout. (1996) Fluconazole treatment of Candidal infections caused by non-Albicans Candida species. European Journal of Clinical Microbiology & Infectious Diseases 15:3, 238-242
CrossRef349
David A. Dean, Kenneth W. Burchard. (1996) Fungal infection in surgical patients. The American Journal of Surgery 171:3, 374-382
CrossRef350
Staci A. Fischer, Gordon M. Trenholme, Stuart Levin. (1996) FEVER IN THE SOLID ORGAN TRANSPLANT PATIENT. Infectious Disease Clinics of North America 10:1, 167-184
CrossRef351
D. Hantschke. (1996) Differentiation of yeast-like fungi using the commercial Auxacolor system*. Mycoses 39:3-4, 135-140
CrossRef352
Karim A. Adal, Barry M. Farr. (1996) Central venous catheter-related infections: A review. Nutrition 12:3, 208-213
CrossRef353
Françoise Meunier. (1996) Current clinical issues on mycoses in neutropenic patients. International Journal of Antimicrobial Agents 6:3, 135-140
CrossRef354
Jose A. Nieto-Rodriguez, Shimon Kusne, Rafael Mañez, William Irish, Peter Linden, Mario Magnone, Edward J. Wing, John J. Fung, Thomas E. Starzl. (1996) Factors Associated with the Development of Candidemia and Candidemia-Related Death Among Liver Transplant Recipients. Annals of Surgery 223:1, 70-76
CrossRef355
J. Klastersky. (1995) Prevention and therapy of fungal infections in cancer patients. Supportive Care in Cancer 3:6, 393-401
CrossRef356
C.J. Wells, G.J. Leech, A.M.L. Lever, M.H. Wansbrough-Jones. (1995) Treatment of native valve Candida endocarditis with fluconazole. Journal of Infection 31:3, 233-235
CrossRef357
J. R. Graybill, R. Bocanegra, M. Luther. (1995) Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis. European Journal of Clinical Microbiology & Infectious Diseases 14:8, 700-703
CrossRef358
Lilyann Novak Frazer, David Moore. (1995) One stop mycology. Mycological Research 99:5, 630-640
CrossRef359
(1995) The Treatment of Candidemia. New England Journal of Medicine 332:16, 1100-1102
Full Text360
J. Berenguer, V. Fernández-Baca, R. Sánchez, E. Bouza. (1995) In vitro activity of amphotericin B, flucytosine and fluconazole against yeasts causing bloodstream infections. European Journal of Clinical Microbiology & Infectious Diseases 14:4, 362-365
CrossRef361
U. Schuler, M. Mölle, G. Ehninger. (1995) Prophylaxe und Therapie von Pilzinfektionen in der Onkologie. Mycoses 38, 45-50
CrossRef362
Lena Jahnson, Erja Chryssanthou, BjÖRn Petrini, Tomas Vikerfors. (1995) Fluconazole Failure in Two Cases of Disseminated Candidosis. Scandinavian Journal of Infectious Diseases 27:4, 421-424
CrossRef363
JulieE. Mangino, StephenA. Moser, KenB. Waites. (1995) When to use fluconazole. The Lancet 345:8941, 6-7
CrossRef364
R.G. Sawyer, R.B. Adams, L.K. Rosenlof, A.K. May, T.L. Pruett. (1995) Effectiveness of fluconazole in murine Candida albicans and bacterial C. albicans peritonitis and abscess formation. Medical Mycology 33:2, 131-136
CrossRef365
Meunier, Francoise, . (1994) Management of Candidemia. New England Journal of Medicine 331:20, 1371-1372
Full Text
- Letters
